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Essay-Memoir
TALES OF INFORMED
CONSENT: FOUR YEARS ON
AN INSTITUTIONAL
REVIEW BOARDt
by
"Bartolo "tt
FROM FEBRUARY 1987 until January 1991 I served on the in-
stitutional review board of a hospital as its volunteer attorney
member; "community lay representative, lawyer" was my official
designation. What follows is a memoir of that service. To preserve
privacy, I have suppressed the name of the hospital and of other
institutions, and have given pseudonyms to all those it was neces-
sary to mention by name.
This is not a law review article in the ordinary sense of the term.
It cites few cases, statutes, regulations, and refers only occasionally
to secondary sources. Instead, my personal experiences and reac-
tions to the experiences of others dominate the work. One could
attempt to affiliate this subjectivity with the recent "narrative turn"
in legal scholarship, but that seems presumptuous to me.
I hope that a reader could use this memoir of my work on an
institutional review board for a few simple purposes. Of perhaps
greatest importance is what my experience has to say about an insti-
tutional review board's oversight of the process of informed con-
sent. The following contains documents that may aid other boards
and board members in discharging this oversight duty. My account
may also be important to those who have served, or who are about
t Several colleagues read an earlier version of this article, and I thank them (albeit
anonymously) for their many helpful comments. I feel constrained to mention that I did not
show the manuscript to anyone with whom I had served on the institutional review board,
and that the editors of Health Matrix, one of whom has served on another institutional review
board in a different state, were unable to verify the events described here.
ft The author, who holds two law degrees, has been a full-time teacher at law schools
in the United States since the mid-Seventies.
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to serve, in such a position. Finally, the adventures of a lawyer
among physicians and other health-trained professionals may be in-
teresting to those in any of these disciplines.
In late 1986 a former law student, whom I will call Barbarina,
telephoned my law school office for assistance. Barbarina had been
an outstanding student and a favorite of mine. After graduation she
had remained in town and eventually became the chief financial of-
ficer of a community children's hospital. On the phone, after an
enthusiastic renewal of acquaintance, Barbarina indicated her prob-
lem: There were two hospital committees required to have attorney
members that currently had no such members, an ethics panel and
the institutional review board; did I have any suggestions?
Barbarina generally described the work of the two committees.
The ethics panel, which considered discontinuation of life-sus-
taining treatment and other similarly weighty issues, tended to meet
in crisis circumstances. I immediately thought of one of my law
school colleagues who had a strong interest in right-to-die cases for
the ethics panel and suggested to Barbarina that she contact that
person.
Placing someone on the institutional review board was a more
difficult matter. The board ("IRB," as she called it) met more regu-
larly-but only once a month-to approve any hospital research
project involving human subjects, including approval of the in-
formed consent form given to the research subjects. Both of the
school's torts teachers were familiar with the law of informed con-
sent and therefore would be likely candidates. But one had already
been on the IRB-his resignation several months before, I was told,
had created the current vacancy-and the other was probably too
busy to take up another responsibility. I said I would talk to the
torts teachers and then get back to Barbarina.
The conversations with my torts colleagues were predictable.
The former member said he had resigned because of concern over
his personal liability for board decisions-a comment that would
trouble me throughout my service on the IRB.' The other torts
teacher professed interest, but did not want to take time away from
teaching, a full slate of off-campus presentations, and family.
About a month after her original call, I telephoned Barbarina to
report my lack of success in finding an attorney member for the
1. See, e-g., Allan Reider, Potential Liability for Institutional Review Boards and
Bioethics Committees, HOME CARE ECON., Fall 1987, at 119.
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institutional review board. After a brief pause, Barbarina re-
sponded, "What about you, Bart?" From the outset I had thought
that she might be interested in having me as a committee member,
but I had avoided the subject. Now that it was out, I quickly listed
reasons why I was unqualified for the job: My main teaching area,
criminal law, bore no relation to the work of the IRB; I had never
even taken a course in medical jurisprudence; I was not a member
of any state bar. Barbarina brushed these disclaimers aside, saying
she was sure that I could do the work.
Of course, this was gratifying to my ego, and I began to sell the
idea to myself. I had always enjoyed working with professionals
from other disciplines,2 and the chance to meet regularly with phy-
sicians, nurses, and hospital administrators began to appeal to me.
More importantly, there was a relationship between the review of
informed consents and my other principal teaching responsibility,
legal research and writing. I already spent much of my time read-
ing the written work product of law students-memos, briefs, and
law review notes and comments-and could sharpen whatever skills
I had acquired in this process by applying them to another type of
legal writing: informed consent forms. So by the end of our second
telephone conversation, I was telling Barbarina that I would likely
take the IRB position.
Further reflection only interested me more, so I was happy to
receive a letter in late February 1987 from the chairman of the
IRB-Dr. Sarastro-thanking me for agreeing to serve on the
board and inviting me to drop by his office before the next meeting.
Enclosed in the letter was a four-page handout of guidelines for the
IRB. Regarding board composition, the guidelines indicated that
the board should have at least five members, that one-third to two-
thirds of the membership should be "scientists," that at least one
member should be "a representative of the community," and that
membership by an attorney and a minister was "recommended";
appointments were for a year, and "[a]lthough some turnover of
membership is desirable, the membership should be relatively stable
from year to year in order to enhance the experience and introduce
stability into the standards of the IRB."3
2. A year or so before, I had commenced what has turned out to be an extensive collab-
oration with a psychology professor.
3. For a discussion of IRB membership requirements and procedures, see George J.
Annas, Ethic Committees: From Ethical Comfort to Ethical Cover, HASTINGS CENTER REP.,
May 1991, at 18; Dale L. Moore, Recurrent Issues in the Review of Medical Research on
Human Subjects, 1 ALB. L. J. ScI. & TECH. 1, 11 (1991).
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The board guidelines also included two separate lists of criteria
for evaluating research projects (formally labeled "protocols") in-
volving human subjects-the second pertaining to protocols involv-
ing children-which I subsequently learned were taken directly
from the applicable federal regulations.4 The criteria bristled with
mandatory but open-textured terms like "appropriate," "equitable,"
"the safest procedures consistent with sound research design," and
"reasonable in relation to the anticipated benefits." The board
guidelines also required informed consent forms that "minimize the
possibility of coercion or undue influence" and "communicate[ ] in
language that is understandable to the subject."
Also in Sarastro's first letter was a four-page set of "Guidelines
for Investigators," directed toward those supervising research, with
a five-page attachment, a blank "Human Research Protocol Form."
Though there was no sample informed consent in the attachment,
the investigator guidelines devoted almost two pages to the in-
formed consent form, beginning with "Experience has shown that
many applications are defective with respect to the informed con-
sent." The investigator guidelines listed the federal requirements:
A fair explanation of the procedures to be followed and their
purposes, including identification of any procedures which are
experimental;
A description of any attendant discomfort and risks reasonably
to be expected;
A description of any benefits reasonably to be expected;
A disclosure of any appropriate alternative procedures that
might be advantageous to the subject, if applicable;
An offer to answer any questions concerning the procedures;
An instruction that the person is free to withdraw consent and to
discontinue participation in the project or activity at any time,
without prejudice to him or herself;
A promise that all information which refers to or can be identi-
fied with a particular subject will remain confidential. 5
The investigator guidelines also contained a lot of advice: "Use lan-
guage that lay people can understand." "Be as explicit as possible
in stating the risks and benefits." "In general, informed consents
4. 45 C.F.R. pt. 46 (1990) (same language as in 1986). See also 21 id. pts. 50, 56 (1991)
(same language as in 1986).
5. The last item contained an additional explanation in parentheses: "That is, that
such information will not be disclosed, except with the consent of the subject or a legally
authorized representative, and as may be necessary for the review committee to fulfill its legal
responsibilities for annual review of the project."
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drawn up by pharmaceutical firms are inadequate for our pur-
poses." "The fact that a particular consent form was judged ade-
quate in another institution does not necessarily mean that it will be
acceptable here."6
Skimming these guidelines gave me a sense that I was getting
involved with a fairly sophisticated operation, with relatively strong
internal procedures. A few days before the second Wednesday in
March, I received at the law school a packet from the hospital's
Quality Assurance Department, which had administrative responsi-
bility for the IRB. The packet included a meeting agenda-ap-
proval of previous minutes, three annual reviews of research
protocols, three new protocols, and one item for discussion (a pro-
tocol recently discontinued for lack of an annual review request)-
and supporting documents for most of the agenda items.
The documents were rather formidable. Two of the annual re-
view documents contained a memo indicating the current status of a
previously approved project (in both cases, there were no new sub-
jects in the project and little or no activity-a common situation, I
learned rather quickly). Attached to each of these memos was a
copy of the informed consent-eight double-spaced pages in one
case and four pages in the other.
The other annual review document was in a form with which I
soon became quite familiar. As most of the physicians in the hospi-
tal were also affiliated with a local university's medical school (not
connected in any way with my law school), which had its own IRB,
many of them chose to submit the university IRB forms to the hos-
pital IRB. The university renewal form was a four-page bureau-
cratic array of lines and boxes to be completed by the investigator.
The directions were short and to-the-point (for example, "Give
your current assessment of the risks and benefits based on the re-
sults," above a two-inch-by-seven-inch box). The form ordered the
investigator to attach an informed consent only if it had been re-
vised. (Like the other renewals in my March 1987 packet, this doc-
ument indicated little activity and no revision of the informed
consent.)
The protocols for new research projects were in general more
detailed. The first was only three single-spaced pages long (includ-
ing informed consent)-such brevity was rare, I discovered soon
6. Another caveat - which was largely ignored throughout my service on the IRB -
read, "If Spanish speaking subjects will be involved in the study, a Spanish version of the
consent form should be provided for review by the Committee." See infra notes 30 & 33.
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enough-but everything about the protocol put me off: its title,
"Use of physostigmine salicylate (Antilirium) as a stimulus for
growth hormone release"; its relentless use of medical jargon (the
following phrases are all from the first paragraph, meant to be intro-
ductory: "GH radioimmunoassay," "endogenous GH secretion,"
"adrenergic, dopaminergic, cholinergic, serotonergic, histaminergic
and gamma aminobutyric acidergic neurons"); and its equally con-
fusing use of medical shorthand ("[B]aseline samples will be taken
at -30, -15, and 0 minutes. At 0 minutes 0.02 mg/kg up to 1.0 mg
will be given I.M."). Rather than try to wade further through this,
I retreated to the informed consent, to discover that the research
involved a drug injection, followed by the taking of blood samples
at fifteen-minute intervals over four hours-a relatively simple pro-
tocol. Thus I learned early on that reading the informed consent
was the best way to understand a protocol, and probably the only
way for those like me without medical training.
Though sponsored by a hospital doctor, the other two new pro-
tocols originated with a Japanese corporation that wanted to experi-
ment with human tonsils obtained through routine tonsillectomies
conducted at the hospital. I could not imagine how this might be
controversial, and concluded from the first packet that while the
work of the IRB might be tedious, it did not seem to be particularly
contentious.
I met with Dr. Sarastro before the meeting. My first impression
of him was that he was cordial in a distant sort of way; my attempts
at ingratiating humor produced candid but unresponsive glances as
frequently as they brought chuckles. After a few minutes of point-
less conversation, Sarastro led me across an enclosed walkway to a
neighboring building, down an elevator to the basement, around a
corner and past a cafeteria, to the designated conference room. I
knew then why Dr. Sarastro had asked me to meet him in his office
before the meeting; I never would have found the meeting room on
my own.
After being introduced to the other board members (about ten
people that day, out of a membership of around fifteen), I kept
pretty quiet. I thought that I should learn the ropes before I be-
came an active participant. So I watched as the IRB approved the
minutes of the last meeting-it surprised me that the minutes were
distributed at the beginning of the meeting and collected at the end;
[Vol. 2:193
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apparently, a hospitalwide policy, but still pretty uptight to me7-
and then gave rather close scrutiny to the three renewals, requiring
minor amendments in their informed consents (spelling corrections
and word substitutions for clarity).
The same attention was given to the new protocols, which were
also approved. Though it was arguable that research with dis-
carded tonsils did not need IRB approval, the group determined for
reasons I did not then understand to retain some review of the ac-
tivities of the Japanese research institute. Occasionally in this dis-
cussion I noticed the peculiarly careful and indirect tone that
professionals employ when they want to raise a concern without
being explicit about it. But I did not catch what their concern was.
Because I had been so reticent at my first meeting, I determined
that I should show my good faith at the second meeting by bringing
a handout of legal materials relevant to the work of the IRB. Be-
sides, finding the correct provisions would require looking at the
Code of Federal Regulations, a source with which a teacher of legal
research should be familiar. After a few false starts, I located the
relevant statutes' and regulations,9 which produced a more sizable
packet than I had expected. Nevertheless, I asked the faculty secre-
tarial office to reproduce twenty copies at school expense, and
brought them to the next meeting.
The agenda for the April meeting included the two renewals
modified at the March meeting, plus several new items. I read the
supporting documents on these new items with a closer eye, flagging
questionable areas based on my limited experience at the earlier
meeting. For examples, one renewal form said that an informed
consent was enclosed, when it was not, and a new protocol con-
tained no informed consent form. But the most interesting parts of
the agenda were six requests from Dr. Selim, the hospital's leading
specialist in pediatric cancer. Each request involved a research pro-
tocol from a nationwide consortium of pediatric oncologists in
which Dr. Selim participates; the consortium conducts numerous
parallel research projects at hospitals around the country. The con-
sortium protocols on the agenda-two new, one for annual review,
and three to be amended-came with lengthy supporting docu-
ments (with unfathomable tables and flowcharts) and informed con-
sents, all produced by the consortium's central office.
7. During my last year on the IRB, the chairman relaxed this policy, apparently
unilaterally.
8. 42 U.S.C. § 289(a) (1988) (same language as in 1986).
9. 21 C.F.R. pts. 50, 56 (1991). See supra note 4.
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Buffaloed by the protocols themselves (one was twenty-six
pages, single-spaced), I turned to their informed consents. Though
somewhat more illuminating, they too were disappointing. The
consent forms used terms that would be unfamiliar to a patient-or,
the more common situation at a children's hospital, a patient's par-
ent-even one with an advanced education: "dose limiting toxici-
ties," "intrathecal injections," "bone marrow aspiration,"
"histopathological material," and "bilateral wedge, testicular bi-
opsy." Not only were these terms opaque, but in many cases their
opacity hid what in reality were rather serious procedures and
consequences.
Each informed consent also contained a sly attempt to limit lia-
bility: "In the event of a research-related injury, I understand that
participation has been voluntary." This language surprised me, for
whatever consortium employee drafted the consent forms should
have known that any such attempt would be ineffective: The federal
regulations regarding informed consent specifically prohibit using
the consent form to limit the patient's legal rights in any way.10
These provisions thus distinguish human research informed con-
sents from the informed consents between doctor and patient that
typically play a role in medical malpractice litigation.
My best recollection of the April 1987 meeting is that I kept my
mouth shut as the other IRB members gave a gingerly treatment to
the consortium protocols. The general impression I had was that
the group was dissatisfied with the informed consents, but was will-
ing to acquiesce in their approval because the consent forms were
being used nationwide, and because they were important to Dr. Se-
lim's work, which in turn was important to the hospital. 1
By the second meeting, I had begun to identify the principal
players among the IRB members. Dr. Sarastro, as his no-nonsense
manner implied, ran a tight but fair meeting. He recognized every-
one who wanted to speak, but usually exerted light pressure to
move on. The principal discussant among the other board members
was Dr. Ottavio, a pediatric endocrinologist in his mid-forties. Ot-
tavio had his own research protocols (in the consideration of which
he took no part, pursuant to board rules), and so brought an investi-
gator's perspective to the IRB meetings. But tempering this possi-
10. 21 C.F.R. § 50.20 (1991); 45 id. § 46.116 (1990).
11. One marker of Dr. Selim's importance was that unlike some other investigators,
Selim never attended an IRB meeting during my time on the board. Barbarina later told me
that while he had a wonderful bedside manner, especially with very ill children, Selim had a
very low tolerance for bureaucracy.
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ble bias was an uncommon empathy for the worried parents of sick
children. I liked Dr. Ottavio almost from the moment I met him.
Somewhat less vocal than Ottavio were Zerlina, a risk manager,
and Reverend Nettuno, the hospital's chaplain. Zerlina had no dis-
cernible medical training, but she was not afraid to express her
opinions. I admired Zerlina's spunk, as I admired Reverend Net-
tuno's compassion. A bearish middle-aged man, Nettuno champi-
oned the rights of patients, frequently implying his disdain for the
way doctors (and lawyers) failed to relate to them as human beings.
While most of the other IRB members were silent or absent-
for example, the community representative-a few occasionally
contributed to the discussion: two nurses, one older, with the air of
a shop steward, and the other somewhat younger and much more
tentative; and Basilio, the hospital administrator. Basilio's manner
was military: He did not really care what the policy was, as long as
it was being followed, to the letter.
Most of the members appeared to appreciate my statutes-and-
regulations handout (though I doubt any of them except Zerlina
read it), and I was soon asked to do a little more research. Because
of the hospital's connection with the local university, a state-sup-
ported institution, the hospital's consent form referred to a specific
statute regarding state liability for injuries received during research;
board members had the impression the statute was relevant to the
work of the IRB, but had no idea what the provision said. It turned
out that the statute was the state's general waiver of sovereign im-
munity and of course said nothing about human research or in-
formed consent. I was surprised by the legal ignorance of a group
of very intelligent people. Why couldn't they have looked up the
statute themselves? They seemed awed by the incantatory power of
legal references; we don't know what it means, just that we have to
include it.
During my first few months on the board, I also did some re-
search on the legal and ethical background of institutional review
boards. Reverend Nettuno circulated some articles on the role of a
hospital IRB, and Dr. Sarastro made available a set of videotapes
that documented the history of the legislation requiring IRB's.
From these sources and some others I found,12 I learned of the
atrocities that had been committed in the name of science-for ex-
12. See, eg., NATIONAL COMM'N FOR THE PROTECTION OF HUMAN SUBJECTS OF Bi-
OMEDICAL AND BEHAVIORAL RESEARCH, THE BELMONT REPORT: ETHICAL PRINCIPLES
AND GUIDELINES FOR THE PROTECTION OF HUMAN SUBJECTS OF RESEARCH (DHEW Pub-
lication No. (OS) 78-0012, 1978).
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ample, a project in which the venereal disease of predominantly
poor black men went untreated for decades'a-and of the public,
scientific, and legislative responses on learning of such events.
Though it was difficult to compare such depraved "research" with
injections and blood tests, or harvesting discarded tonsils, this study
made me more aware of the underlying reason for the IRB and for
participation in it by people like me.
So when I received the packet for the May meeting, which con-
tained several protocols with informed consents that were unsatis-
factory to me (some from Dr. Ottavio and some from Dr. Selim), I
decided I had to speak up. Part of my thinking was that as an out-
sider, I could take potshots without risking my status in the institu-
tion-I had none-unlike virtually all the other members of the
IRB, who were economically dependent on the hospital to one de-
gree or another. Further, I began to feel obliged to play the gadfly;
I owed it to the patients and their parents and to the other members
of the IRB.
Despite my legal training, this role was not one I took to easily.
I had never practiced law, so I had never sharpened my skills at
being obdurate. Even as a law teacher, I had eschewed the con-
frontational "Kingsfield" style, opting for a more relaxed class-
room. But at the meeting I cleared my throat and launched into an
overheated attack on various defects in the informed consents: use
of medical jargon, other defects in clarity, and spelling and gram-
mar mistakes. My outburst was calmly received, and Dr. Sarastro
managed to soothe me by responding to some of my concerns. In
return, I softened my demands, and all of the protocols were ap-
proved with minor revisions in the informed consents. While recog-
nizing that I had been coopted, I thought I had made a dent.
Over the next several months I continued to play my role. I was
expected to find fault with most of the informed consents, and I
usually lived up to this expectation. Sometimes I adopted a ques-
tioning, "I really don't know what I'm talking about, but" tone;
sometimes I was more derisive. And usually I had some support,
from Zerlina, Reverend Nettuno, or one of the nurses-either
seconding my comments or adding criticisms of their own. But our
efforts produced only trivial amendments (which Dr. Sarastro be-
13. See Allan M. Brandt, Racism and Research: The Case of the Tuskegee Syphilis
Study, HASTiNGS CENTER REP., Dec. 1978, at 21.
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gan to handle on his own, rather than bringing them back to the
board).
Some of the more extreme defects I complained about during
my first year on the IRB included an informed consent that ended
in its middle; either no one had bothered to finish the form, or no
one had bothered to check the copies that were distributed to the
review board. On another occasion the research protocol listed ste-
rility as "a likely complication" of one of the drugs to be adminis-
tered under the protocol, yet the informed consent made no
mention of this potential side effect.
One of the requests for annual renewal during this period read
in its entirety: "Registrations: One. Patient died an early death due
to drug toxicity." Given this outcome, I wondered why the re-
search was being continued. And one physician, using the univer-
sity annual renewal form, answered the questions exactly as written
below:
Describe the experience of these subjects, i e., benefits, adverse ef-
fects, withdrawals from research.
The natural history of Transposition of the Great Arteries with
medical surgical intervention has been reviewed. A compilation
of results is available to date. Since the review is observational,
no affect [sic] has been noted on the subjects.
What are the results of the research? Detail as applicable: - for
Continuing Review include results to date...
Results of the research indicate that the first year survival follow-
ing medical surgical treatment is excellent in transposition. The
arterial switch operation has the highest mortality rate. The Sen-
ning operation is next. The Mustard is least. There are many
suddleties [sic] and complexities under study at this time.
Give your assessment of the risks and benefits based on the results.
Current assessment of the risks and benefits: The date [sic] are
yet incomplete and have not influenced our treatment of patients
at this time.
Detail any new information that has come to light since the last
IRB review of this project which may relate to this subject's will-
ingness to continue participation.
New information has been voluminous and a copy of this will be
lent to the I.R.B. at th [sic] time of review.
No explanatory material accompanied the renewal request. Be-
cause of the evident vacuity and sloppiness of the request, I told the
other board members that it was "the kind of document a plaintiff's
attorney would kill for."
Despite these few problems with annuals renewals, the IRB was
devoting the bulk of its meeting time to the informed consent forms,
HEAL TH MATRIX
with most of them going back to the researchers for some amend-
ment. Attempting to short-circuit this process, Dr. Sarastro asked
me to draft proposed guidelines for the forms, to be distributed to
researchers before they submitted anything to the IRB. I was
pleased with the assignment, and went through the informed con-
sents I had seen during my brief tenure, noting what I liked and
what I disliked. After again consulting the applicable federal regu-
lations, I drafted the following guidelines and sent them to Sarastro,
with a request for input; I was flabbergasted when he sent them on
to the IRB membership with no changes at all.
Elements of an Informed Consent Form
1) Each informed consent form should begin with a heading
containing a short title of the study and indicating the sponsoring
institution(s).
2) The first sentence should indicate the signer's consent to par-
ticipate in the study. Example: "I, , willingly agree to
allow my child, , to participate in this study to assess
.... " This description of the study in this sentence should be
brief.
3) The next sentence(s) of the form should describe the underly-
ing condition that qualifies the subject for participation in the
study. Because it is assumed that this condition is already well
known to the signer, this description may use technical terms
otherwise unacceptable in an informed consent form. If this as-
sumption is incorrect, technical terms should be avoided.
4) The next paragraph(s) of the form should describe, in lay-
man's terms, the procedures that will be followed in the study.
Use of layman's terms means that all procedures, including rou-
tine ones, should be described, in terminology understandable to
a person of no more than ordinary intelligence with no special
knowledge of medicine.
5) The next paragraph(s) of the form should indicate, in lay-
man's terms, the risks of participation in the study, including the
potential side effects of all therapies to be employed.
6) The potential benefits of the study, both generally and specifi-
cally to the participants in the study, should be included in the
form. Once again, the description should be in layman's terms.
7) The form should include a statement that participation in the
study is voluntary, that the subject may refuse to participate or
withdraw at any time, and that neither refusal nor withdrawal
will result in any penalty or loss of benefits. Alternative proce-
dures available to a nonparticipating subject should be described,
in at least general terms.
8) A statement indicating the degree of confidentiality to be ac-
corded study results should be included.
[Vol. 2:193
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9) The form should include the following sentence: "In the
event that physical injury occurs as a result of these procedures,
treatment for injury of my child will be available at [the
h]ospital. I understand, however, that I will not automatically
be provided with reimbursement for medical care or receive
other compensation."' 4
10) The form should indicate the names and telephone numbers
of those principally responsible for the study, along with a state-
ment that these persons may be contacted for additional informa-
tion about the study, both before and after signing the form.
11) The form should conclude with a statement that the signer
has read all of the consent form, has had the opportunity to ask
questions and to receive answers, and has decided to consent to
participation in the study. There should also be an acknowledg-
ment of the fact that a written version of the consent form will be
provided to the signer.
12) There should be signature lines, with accompanying lines for
dates of signature, for the parent(s) or legal guardian of the sub-
ject, the subject (if appropriate), and the principal investigator.
Outside counsel for the hospital had previously recommended the
specific language in item 9. IRB members, especially Basilio who as
chief administrator dealt directly with the hospital's law firm, con-
sidered its inclusion essential. After a perfunctory discussion, the
IRB approved the guidelines.
While the guidelines had little immediate impact on the re-
searchers, I was surprised when they seemed to change the behavior
of some of my IRB colleagues. At one meeting after their distribu-
tion, I indicated that I had no problems with a particular informed
consent, and we were about to move on in the agenda when Zerlina,
the risk manager on the board, launched into a detailed analysis of
the form, noting many problems I had missed. Chagrined at my
oversight, I was also pleased; I felt partially responsible for energiz-
ing her, either by precept (through the guidelines) or by example
(through my continual carping over the preceding months).
1988 brought a few new members to the IRB. One of the nurses
on the board left and was replaced by Despina, whose attitude to
the IRB's work was quite practical. Also new, or perhaps just no-
ticed by me, was Pedrillo, head of the hospital's pharmacy. Pedrillo
seemed painfully shy. He rarely participated in the discussions, and
when he did, he seemed frustrated at his inability to express himself
as clearly as he would have liked.
14. My proposed guidelines contained the full name of the hospital.
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Dr. Alfonso was the most notable of the new members. He
came from the hospital's immunology department, which per-
formed a lot of bone marrow transplants. The informed consents
received from immunology were quite good, except for their overly
sophisticated language. I had derived many of the recommenda-
tions in the guidelines from them, as well as from those submitted
by Dr. Ottavio. At one meeting Dr. Alfonso let it slip that he was
primarily responsible for drafting the immunology consent forms.
Alfonso, who cast the image of a connoisseur of good food and
wine, was certainly a connoisseur of good writing.
While Alfonso knew how to write acceptable informed consents,
he was deeply skeptical of the IRB process. He would erupt every
few meetings with the criticism that no piece of paper can assure
adequate communication between physician and patient. He felt
that true informed consent involves a conversation over several
hours, if not days, and that the IRB was merely creating another
paperwork hoop for doctors to jump through. I usually chimed in
that these requirements were for the unethical practitioners, those
who cared not at all about patient communication or patient rights.
The IRB imposed minimum standards which good physicians
should routinely exceed. Because my rejoinder never satisfied Dr.
Alfonso, we repeated this exchange several times during our tenure
on the board.
Another of Alfonso's complaints was the cost of the paperwork.
Under hospital policy, each department's budget included copying;
a single research proposal, if submitted to both the hospital and uni-
versity IRB's, might involve well over 1000 pages of copies. Sur-
prisingly, the board spent considerable time discussing the problem
of excessive copying, which I deemed one of the costs of doing re-
search. When someone seriously suggested that incomplete applica-
tions be distributed-some IRB members would get the research
protocol, while others would get the informed consent-I put down
my foot. I certainly was not going to vote favorably on any re-
search protocol I had not read; the prospects for civil liability were
just too high. Raising the twin specters of litigation and liability
scares most people, especially those in the medical field. And it
usually stops the conversation, as it did in this instance.
Institutional liability was almost as great a concern as personal
liability. In discussing one research protocol involving an experi-
mental surgical device, board members thought that the company
making the device should indemnify the hospital. The company re-
fused and indicated that it had entered into an indemnity agreement
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with only one hospital in the nation, a prestigious institution with
which the company strongly desired to work. The implication was
that our hospital was not in this category.
Our researcher intended only "compassionate use" of the de-
vice. This means the device could be used in only a few extreme
cases where no other therapy appeared likely to succeed. While not
true research, compassionate use was nevertheless subject to the
IRB process. Asked to research the potential liability of the hospi-
tal and its employees during compassionate use of an experimental
device, I referred the matter to my student assistant at the law
school. He eventually gave me a twenty-one-page handwritten
memo on the subject.
Although my student assistant was bright, he was an outsider to
the IRB process. He misunderstood what I wanted and the memo
was largely irrelevant. What struck me most about the memo,
though, was how specialized my knowledge of institutional review
boards had become in little more than a year on the job. My legal
questions were so narrow that I could not even sensibly convey
them to an intelligent law student. If he had sat with me through
the monthly meetings, he would have understood my questions in a
moment. But he had not, and it was as if I was asking him to ana-
lyze the behavior of an aboriginal tribe. So I realized that it took
insiders to evaluate the IRB process.
Throughout my service on the IRB the hospital fretted about
the regular visits from Food and Drug Administration inspectors;
any deficiency noted by these inspectors could result in serious
problems for the hospital. So when an FDA inspector suggested in
March 1988 that the resumes of IRB members needed to be on file
with the hospital, we all submitted our resumes. When the inspec-
tor said the IRB should have recorded votes on each research pro-
posal, Dr. Sarastro began taking recorded votes. And when the
FDA said the IRB needed better guidelines on emergency review
and on conflicts of interest, we spent the better part of one meeting
redrafting Sarastro's proposed guidelines.
The FDA had even more suggestions three months later. First,
the IRB needed a policy for determining which research projects
required review more frequently than every year. Second, the board
"[n]eed[ed] to insure that [it was] applying the appropriate consid-
erations in regard to the informed consents." When Dr. Sarastro
circulated these FDA suggestions to the board, his only amplifica-
tion of the latter remark was to append copies of the applicable fed-
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eral regulations.15 The board acted on the first suggestion, but the
second was referred to me.
Closer review of the applicable regulations caused me to make
several changes in the previous guidelines.16 I added a number of
specific requirements mentioned in the regulations: to indicate the
purposes of the research and its expected duration, to label as "ex-
15. 21 C.F.R. § 50.25 (1991).
16. The revised guidelines read as follows:
Elements of an Informed Consent Form
1) Each informed consent form should begin with a heading containing a short title
of the study and indicating the sponsoring institution(s). Subheadings for the vari-
ous parts of the form indicated below are strongly recommended.
2) The first paragraph should indicate the signer's consent to participate in the
study. Example: "I - willingly agree to allow my child, - , to par-
ticipate in this study to assess. . . ." This description of the study should specify
that the study involves research and should explain the purposes of the research and
the expected duration of the child's participation in the study.
3) The next paragraph(s) of the form should describe, in lay terms, the procedures
that will be followed in the study. Use of lay terms means that all procedures,
including routine ones, should be described in terminology understandable to a per-
son of no more than ordinary intelligence with no special knowledge of medicine.
All experimental procedures should be identified as such.
4) The next paragraph(s) of the form should indicate, in lay terms, the risks of
participation in the study, including the potential side effects of all therapies to be
employed.
5) The potential benefits of the study, both generally and specifically to the partici-
pants in the study, should be included in the form. Once again, the description
should be in lay terms.
6) The form should include a statement that participation in the study is voluntary,
that the subject may refuse to participate or withdraw at any time, and that neither
refusal nor withdrawal will result in any penalty or loss of benefits. Alternative
procedures available to a nonparticipating subject should be described.
7) A statement indicating the degree of confidentiality to be accorded study results
should be included. This statement should specify that the Food and Drug Admin-
istration may inspect the study records.
8) The form should include the following paragraph: "In the event that physical
injury occurs as a result of these procedures, treatment for injury of my child will be
available at [the hlospital. I understand, however, that I will not automatically be
provided with reimbursement for medical care or receive other compensation. For
further information on this subject, please contact [Basilio, the hospital administra-
tor] at [his hospital telephone number]."
9) The form should indicate the names and telephone numbers of those principally
responsible for the study, along with a statement that these persons may be con-
tacted for additional information about the study, both before and after signing the
form.
10) The form should conclude with a statement that the signer has read all of the
consent form, has had the opportunity to ask questions and to receive answers, and
has decided to consent to participation in the study. There should also be an ac-
knowledgment of the fact that a written version of the consent form will be pro-
vided to the signer.
11) There should be signature lines, with accompanying lines for dates of signature,
for the parent(s) or legal guardian of the subject, the subject (if appropriate), and
the principal investigator.
I put Basilio's name and telephone number in section (8) merely to tweak him. The IRB
changed this portion of the guidelines to recommend contacting the hospital's Quality Assur-
ance/Risk Management Department.
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perimental" the use of any such procedures, to acknowledge that
FDA officials may have access to the research records, and to iden-
tify a person to contact regarding reimbursement of research-re-
lated costs. I also removed the requirement of discussing the
patient's underlying condition, to which the federal regulations did
not refer. There were also some new stylistic touches-most nota-
bly, a suggestion to use subheadings, and removal of some sexist
language in the guidelines themselves (substituting "lay" for
"layman's").
There were complaints among IRB members about the in-
creased size of the guidelines and the consequent lengthening of the
consent forms. But it was difficult to argue against items specifi-
cally required by applicable regulations. The board approved the
new guidelines with the most significant change being the addition
of a section on paying the cost of the research: "A clearly defined
statement as to the cost of the study. If the costs are not covered by
usual reimbursement mechanisms, the responsibility of the subject
and family must be defined." 17
Another apparent response to the FDA's suggestion regarding
the hospital's informed consent process was to seek the opinion of
outside counsel. Outside counsel turned out to be Cherubino, a for-
mer student, who was a senior associate at one of the "better" local
firms. Cherubino's three-page letter was rather superficial, but I
supposed that his problem was the same as my student assistant's:
Though Cherubino could read the regulations as well as I, he lacked
the insight that comes from actual involvement in the process.
Another problem was Cherubino's writing style. His letter be-
came the butt of a lot of sarcastic comments about why lawyers
write in an incomprehensible way. My response was to sheepishly
admit that I had been one of Cherubino's legal writing teachers.
While most IRB members would have ignored the letter, the hospi-
tal administration insisted on implementing one of Cherubino's rec-
ommendations-that informed consents include the following
language:
I am aware that [the h]ospital does NOT provide emergency
room care. In the event that physical injury does occur as a re-
sult of these procedures, emergency treatment should be sought
at the nearest facility and if appropriate, additional follow up
treatment will be available at [the h]ospital. For further informa-
tion on this subject, please contact the Quality Assurance/Risk
17. This language became section (12) of the revised guidelines. See supra note 16. I did
not draft this section.
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Management Department at [the h]ospital, [that department's
telephone number].
While I felt there were many ways to improve this language, what
offended me most about it was the "NOT"; capitalizing and under-
lining the word reeked of lawyers. But the hospital administration
had paid good money for the language, and was determined to use
it, "NOT" and all.
In the summer of 1988 Dr. Sarastro surprised us by announcing
that he was leaving the hospital to become dean of a medical school
in another state. Though I had never been close to Sarastro, his
announcement made me realize that I had come to rely on his
steady guidance of the IRB. I worried that a different personality in
his successor could change the IRB, and thus change a setting that I
had grown to enjoy.
Dr. Ottavio presided as interim chair for a month and then we
met our new leader, Dr. Figaro. Figaro was quick when Sarastro
would have been deliberate, glib when Sarastro would have been
reticent. While new to the IRB, Dr. Figaro was a member of the
immunology group and he had participated in many Dr. Alfonso's
research projects. One of Dr. Figaro's first acts was to ask the IRB
if it objected to having his father, a retired physician, sit on the
board. The request surprised me mildly, but like the other mem-
bers, I thought one more opinion would be helpful.
Figaro's initial months as chairman were relatively uneventful.
The board discussed whether it had to review a research project
that included only a questionnaire. (It seemed a little strange to
require the language beginning "In the event that physical injury
occurs as a result of these procedures"; one wag asked how injury
was likely to occur-"from a broken pencil, maybe?") Another
meeting saw a discussion of a recent California intermediate appel-
late court decision,"I holding that a research participant had a prop-
erty interest in a valuable medical product that the researchers had
developed from the patient's removed body parts. The IRB also
devoted considerable time to preparing an orientation packet for
new members.
Preparing the packet made it apparent that the hospital had sev-
eral inconsistent policies regarding the IRB. For example, an un-
dated set of policies I had never seen before required that all board
18. Moore v. Regents of the Univ. of Cal., 249 Cal. Rptr. 494 (Cal. Ct. App. 1988), aff'd
in part, rev'd in part, 793 P.2d 479 (Cal. 1990). See infra text accompanying notes 37-38.
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decisions be unanimous. This practice was never followed during
my time as a member. The same document mandated distribution
of the paperwork on each research project two weeks prior to the
monthly meeting. In actual practice, the Quality Assurance De-
partment tried to get the IRB paperwork out a week before the
meeting, but I rarely received my packets more than five days in
advance.
The board ironed out these inconsistencies, but a few were more
intractable. For example, hospital policy required that one of the
participants be a psychologist. However, I had never attended an
IRB meeting which included the hospital's psychologist, a hospital
employee who was supposedly a member of the board. Basilio's res-
olution of this problem was simple: "He's my employee. I'll order
him to come." Another hospital policy indicated that at least one-
third of the board members should be "scientists." This minimum
could be met only if the nurses and other medical nonphysicians on
the board fell into this category. During a meeting I asked Despina
if she considered nurses like herself scientists, and she bluntly an-
swered, "No." The hospital solved this problem, probably inadver-
tently, by increasing the number of physicians on the IRB.
Expansion in the IRB's membership came soon after the begin-
ning of 1989, and it changed the board dramatically (though not as
dramatically as it would be changed two years later). Most of the
new physician members 9 were Figaro's contemporaries, perhaps a
decade younger than Drs. Ottavio and Alfonso: Dr. Ferrando, a
male, who spoke with an accent that was difficult to follow at times;
Dr. Almaviva, an extremely pleasant woman; and Dr. Susanna,
who had recently relocated to the area with her lawyer husband
from a university hospital in another state. A few months before,
Dr. Figaro had circulated that hospital's informed consent guide-
lines for comparison purposes, and now I guessed who had given
them to him.
Dr. Titus, one of the new members, did not fall into the same
age bracket as his cohorts. In contrast to the other new members,
he was old enough to have treated one of the secretaries at my law
school when she was a child. Two other secretaries had taken their
now teenage children to Titus, and they all spoke warmly of him. I
19. There was also a new community representative, the mother of one of Dr. Ottavio's
patients, who was much more active in IRB affairs than her predecessor had been. The new
community representative remained on the IRB until the fall of 1990, when she withdrew for
personal reasons.
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too would get to know and appreciate Dr. Titus a great deal, be-
cause of a new organizational plan for the IRB introduced in Febru-
ary 1989.
The packet sent to me for the February meeting was unusually
thin; it contained only one research project. The skimpy individual
reading assignments were the result of dividing the board into three-
person subcommittees and asking each subcommittee to consider
only one project. The subcommittees were to convene fifteen min-
utes prior to the board meeting. The subcommittees were then ex-
pected to present their decisions for ratification by the full IRB.
This reorganization of the committee's work pattern incensed
me because I felt it was yet another ploy to reduce copying costs.
Nevertheless, I dutifully met with the other members of my sub-
committee: Pedrillo, the hospital pharmacy supervisor-finding
him occasioned my first and last trip to the hospital pharmacy-and
a new board member, a physician who never made it to the subcom-
mittee meeting, and who attended only a few IRB meetings before
quitting.
Later at the board meeting, I reintroduced my concern about
voting on research projects when I had read neither the protocol
nor the informed consent. I once again raised the liability issue, for
it was easy to envision how a good attorney would cross-examine an
IRB member who had given such a blank check to his colleagues.
Other board members soon expressed dissatisfaction with the
new procedure, and I had the feeling that Dr. Figaro had been skep-
tical about it from the start. By meeting's end we had a new "new
procedure": The subcommittees would remain, with the members
of each subcommittee receiving full documentation on each re-
search project assigned to it, but instead of getting nothing, the rest
of the IRB would receive a short-form description of the project
(usually the university IRB cover sheet) and the informed consent.
Of course, this did not fully satisfy the concern I had voiced. But
not getting the research protocols was a minor loss to me, as I
rarely understood them anyway.
The next month when my quite thick packet arrived, I found
that my subcommittee now had two new members. One was Dr.
Titus. Despite our different backgrounds, Titus and I had roughly
the same anxieties about research involving children and about the
process of informed consent. The other member, another new physi-
cian on the IRB, never made either a subcommittee or a board
meeting. Titus and I continually had trouble finding a reliable third
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member for our group so we simply had our subcommittee "meet-
ings" over the phone.
Titus seemed awfully mercurial to me. One month he would be
astounded at the medical risks to which researchers planned to ex-
pose children -a project involving spermatic cord injections partic-
ularly set him off-while the next month his approach would be
much more permissive. Regarding consent forms, he was just as
likely to condemn all the ones we were to review as "too compli-
cated," as to accept them all with a wry but weary smile. Dealing
with Dr. Titus, like other physicians, reminded me that consistency
was the hobgoblin of legal minds and that other professions had
different sacred cows.
Titus' lack of consistency was frustrating at first because it was
so hard to pin down the sources of his dissatisfactions (which I had
to do in order to explain them to the rest of the board, on the few
occasions when Titus could not attend the board meeting2°). But
ultimately I grew to enjoy the physicians' lack of consistency, as
compared to lawyers, because it seemed more interesting, more
human, and more real.21
Reality in a different form hit the IRB in the first half of 1989.
Switching to the subcommittee system-which was intended to save
meeting time, as well as paper-was itself a time-consuming pro-
cess: The board spent parts of some meetings discussing the sub-
committee system, and thus fell behind in its business. So we
lengthened the meetings. Adjourning at 5:00 became out of the
question; 5:30 or 6:00 was far more common. But still much of
February's work ended up on the March agenda, and much of
March's on the April agenda.
Then in May a thunderstorm struck: annual reviews of thirty-
four of Dr. Selim's projects for the national consortium of pediatric
20. Considering our inability to hold a third subcommittee member, Dr. Titus' absence
meant that there was no medical professional present at the IRB meeting who had reviewed
the protocols assigned to our subcommittee. Approving research projects under these cir-
cumstances made me very uncomfortable, and I occasionally suggested delay. But typically I
would acquiesce to the board's desire not to make researchers suffer because of the absences
of other board members.
21. Dr. Figaro's father also provided many vivid examples of what struck me as incon-
sistency. First he would fume about research defects that seemed minor to me, but later he
would offer apologist explanations for oversights that were inexcusable in my opinion. I
could never predict what would set him off, and was glad that we rarely sat on the same
subcommittee. But I greatly enjoyed our social chats (he and I had a habit of arriving early
for the IRB meetings, and would talk over the cookies and soft drinks the hospital provided),
in which he was unfailingly warm and engaging.
HEALTH MATRIX
oncologists. These assignments came as an addition to the IRB's
usual workload. Later I heard that Selim had allowed a lot of
paperwork (like applying for IRB annual reviews) to slide, and so
feared that a forthcoming consortium inspection would jeopardize
his participation in that group.
This deluge of renewal requests raised the old problem of the
consortium's consent forms, which the hospital had previously al-
lowed Dr. Selim to use.22 But as the board had developed more
specific standards for informed consent, the consortium consent
forms became less and less acceptable. Discontent at the forms,
compounded by discontent with the volume of the renewals, pro-
duced a revolt: Though we approved the renewals requested, the
IRB served notice that it would no longer accept the consortium's
informed consent forms. In the future Dr. Selim was going to have
to produce forms that followed the board's guidelines.
Most board members sensed that Selim himself would never do
this work. Thus in June when Figaro introduced a new IRB mem-
ber, a member of Dr. Selim's staff named Papagena, there was little
surprise. Her task, which was soon to become a major responsibil-
ity, was to act as emissary between Selim and the IRB.
We were already overburdened by this flood of work. However,
in the first half of 1989 the IRB took on new assignments. In
March the board split into two large subcommittees, one to address
policies and procedures and the other to focus on informed consent.
Dr. Ottavio chaired the former subcommittee, which was to study
interaction with the university IRB and standards for exempt re-
search and expedited review.23 Dr. Figaro asked me to chair the
informed consent subcommittee, and I requested Dr. Susanna as a
co-chair. The primary mission of the informed consent subcommit-
tee, as stated in a list of "Issues to be Addressed," was to "[d]evelop
standardized content/verbiage for Informed Consent. (Put on
floppy disk & make available to researchers)."
Dr. Figaro's initial plan was to devote some of the scheduled
IRB time to meetings of these major subcommittees. But as the
IRB meetings grew longer, it became apparent that this plan was
22. The IRB had previously required only minor modifications in the consortium's con-
sent forms-most notably, shoe-homing the "I am aware that [the h]ospita does NOT pro-
vide" language into the margins of the consortium docket.
23. Dr. Ottavio's subcommittee reported back in November 1989 with detailed recom-
mendations regarding "Emergency (Compassionate) Review." As I recall, the IRB approved
these recommendations with minor changes. The board also revamped its protocol amend-
ment form at approximately the same time.
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not going to work. So even though none of us wanted to commit
more than one afternoon a month to the IRB, the subcommittees
began to meet in between the monthly board meetings. The first
informed consent subcommittee meeting was on May 17th. While
the subcommittee had almost a dozen members, the most active
were Dr. Susanna, Dr. Almaviva, Dr. Figaro's father, Reverend
Nettuno, Despina, and Zerlina (who was not even officially a sub-
committee member).
For this meeting I made a open-ended list of "my conception of
the work facing the subcommittee," under general headings such as
where in the consent form standardized language would be appro-
priate, how to encourage use of lay language in the portions where
standardization was impossible, and a catchall for miscellaneous
headaches like use of "he/she" and "I/my child." Though I had
my own ideas of how a standardized form should look, I did not
want the other members of the subcommittee to feel that I was jam-
ming something down their throats.
It was apparent from our first meeting that we were all pretty
much patient-centered. For example, we wanted informed consent
forms that a person with a seventh grade education could under-
stand without much assistance from the doctor or nurse who might
be trying to get the patient to sign. I think we all sensed that there
were others on the board (I thought of Dr. Alfonso and of Basilio)
who would not agree with this goal, but we all seemed determined
to pursue it.
The subcommittee work progressed well throughout the late
spring and summer of 1989. I prepared a memo of the actions
taken at the May 17th meeting, which I distributed along with pho-
tocopies of the chapter of Rudolf Flesch's How to Write Plain Eng-
lish24 that explains the Flesch Readability Chart, a device for
scoring the comprehensibility of English prose by grade level. Dr.
Susanna presided at a subcommittee meeting on May 3 1st, and pro-
duced her own summarizing memo. After a third meeting on June
21st, the subcommittee had a six-page list of guidelines for drafting
an informed consent. Then we set about the task of actually draft-
ing the standardized language.
The other subcommittee members were more than happy to let
Dr. Susanna and me split the task of initial drafting. She took the
first half of the informed consent-where there would be a lot of
variation, because of the need to describe the particular research
24. RUDOLF FLESCH, How TO WRITE PLAIN ENGLISH 20-32 (1979).
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and its risks and alternatives-and I took the last half, where virtu-
ally all the consent forms would be identical (for examples, "Paying
the Costs of the Research," "Physical Injury Resulting from the
Research," "Confidentiality," and so on).
Drafting language for the last half of the informed consent was
more difficult than I expected it to be. I had models for all the
sections I drafted (many of them from Dr. Alfonso's informed con-
sents), but they were all more complex than the subcommittee
wanted. So I spent hours "dumbing down" the language: splitting
sentences into shorter and shorter ones, substituting short words for
long ones. When I had finished, I scored parts of the document on
the Flesch Readability Chart, and was very disappointed to find
that most of the sections I had drafted required a reader with a
twelfth grade education. 5 Though I knew it was possible to sim-
plify the language further, I mailed my draft to Dr. Susanna-and
went on vacation.
Sometime after my vacation (and hers, I believe), I received
Susanna's corrections of my sections and the draft of her sections as
well. Because I had very few suggested changes for her draft, we
merged the two halves and presented them to the subcommittee at a
meeting in September. After contrasting the "rubberstamp" nature
of the IRB years before with what it was becoming, the subcommit-
tee made minor changes in the proposal, and forwarded it to the
board in October.
Surprisingly enough, the IRB made few changes in the docu-
ment. Dr. Alfonso did not complain (much) about the additional
burden on researchers, and Basilio did not mourn the passing of the
"NOT ' language (which I had excised, in a fit of self-satisfaction).
The board added some language here and there, rearranged some
portions of the proposed draft, and appended a three-page glossary
of lay language (which we drafted by individually submitting sug-
gested terms and their simplified replacements to Dr. Figaro).26
25. Several months later a computer analysis of the form finally approved by the IRB
indicated that it was readable by a person with a tenth or eleventh grade education.
26. The glossary read as follows:
5 nil One Teaspoon.
Acromegaly A condition in which excessive growth of soft tissues &
bones occurs as a result of excessive secretion of growth
hormones.
Adolescent Young adult.
Allergic Reaction Fever, chills, rash, nausea, difficulty breathing, or low
blood pressure.
Alopecia Temporary loss of hair.
Anorexia Loss of appetite.
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But the form ultimately approved by the IRB-in December 1989,
after postponing consideration because of the press of business at
Antibody
Antidote
Antiviral
Aplastic Anemia
Arrhythmia
Aspiration
Assess
Bacteria
Biopsy
Bloodwork
Bone Marrow
Bone Marrow Aspiration
Cannula
Catheter
Central Line, Broviac
Chemotherapy
Colon
Cytomegalovirus (CMV)
Decontaminated
Device
Dysfunction
Enzyme
Graft vs. Host Reaction (GVHR)
Hematuria
Hepatic Dysfunction
Hepatitis
Hyperpigmentation
Hypertension
Hypopigmentation
IV Push
Immuno Function
Immunosuppressive Agents
In Vitro
Inadequate
Inflate
Injection
Interdermal
Interferon-gamma
Intravenous
Irradiation
Leukopenia
Local Anesthesia
MRI Scan
Meningitis
Milligram
Monitor
Myocardial Damage
That substance in the blood that blocks the activity of
other substances and helps fight infection.
A remedy that counteracts something undesirable.
A substance that fights viruses.
A disease when bone marrow fails to produce normal
blood forming cells.
Irregular rhythm of the heart.
Removal with a syringe.
Find out.
Germs.
Removal of a small piece of tissue.
Blood studies.
The body's "factory" that makes the blood cells.
A needle is put into bone in order to remove marrow
(blood forming cells).
Tube or needle.
Plastic or rubber tube.
A plastic catheter placed, under general anesthesia, in a
large blood vessel which goes to the heart.
Anti-Cancer drugs.
Large intestine.
A virus infection.
Germ Free.
Instrument.
Impairment or disturbance in functioning.
A substance that causes the breakdown of a naturally
occurring chemical in the body.
Cells of the transplanted tissue react against the tissue of
the recipient.
Bloody urine.
Liver doesn't work correctly.
Liver inflammation.
Darkening of normal skin color.
High Blood Pressure.
Loss of normal skin color.
Give quickly through a small needle into a vein.
The defense system of the body.
Something that prevents the defense system of the body
from working.
In test tubes.
Too low, not enough.
Open up.
Shot, given through a needle.
Given just beneath the skin.
A substance that is naturally present in the human body
which is used by the body to strengthen its ability to
fight infections.
Given through a small needle put into a vein.
Exposure to high doses of radiation.
A decrease in the white blood cells in the body which
increases the tendency for infection.
Numbing medicine.
A type of X-ray exam.
Infection of the lining of the brain.
1/28,000th of an ounce.
Watch, observe.
Injury to the heart muscle.
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the two previous meetings-was quite close to what the subcommit-
tee had proposed.
Because most of the research projects at the hospital involved
children, who could not give legally valid consent,27 the form ad-
dressed itself to the parent of a research subject. After a standard-
ized description of research and informed consent (lifted from
language appearing in virtually all of Dr. Alfonso's informed con-
sents), the first half of the form contained directions for describing
the research and its risks, benefits, and alternatives:
Neurotoxicity Causing damage to nerves (should explain what the
patient will experience)
Non-pathogenic Does not cause disease.
Osteoporosis Weakening of the bone caused by a loss of minerals.
Palliative To provide relief without curing.
Perforate Tear.
Performed Used - do.
Photosensitivity Sensitivity to light.
Platelets Cells that help the blood clot, prevent and correct
bleeding.
Primary Original
Proteinuria Protein in the urine.
Random Picked by chance.
Recumbent Lying flat on back.
Recurrent Returning.
Red Blood Cells Carry oxygen.
Regime Plan.
Reimbursement Payment.
Relapse Disease recurrence
Remission Return to a disease free state
Retinitis Eye infection.
Sensor Able to read.
Sodium Salt
Sterility Inability to have children.
Subcutaneous Given under the skin, into the fatty tissue.
Syndrome Condition.
Therapy Treatment.
Thrombocytopenia Low number of cells that help the blood clot.
Toxicity to Peripheral Nerves Numbness, tingling
Transient Temporary
Venipuncture Blood test.
White Blood Cells Fight infection.
27. The informed consent subcommittee spent considerable time discussing whether it
was psychologically advisable to seek the assent of the child, even though such assent was
legally irrelevant. The IRB ultimately decided to add a child's assent form to the standard-
ized informed consent, but with an option to forgo obtaining assent, provided that the re-
searcher gave a written reason for exercising the option. See infra note 28. But the board
never definitively determined when the child's assent was necessary. See infra text proceed-
ing note 40.
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INFORMED CONSENT
Title of Research Study:
Principal Investigator:
Co-Investigators:
CLINICAL RESEARCH AND INFORMED CONSENT
"You are being asked to allow your child to take part in a clinical
research study. The doctors at [this h]ospital study the nature of
disease and try to develop better methods of diagnosis and treat-
ment. This is called clinical research. In order for you to decide
whether you should agree to allow your child to be part of this
study, you should understand enough about its risks and benefits
to make an informed decision. This process is known as in-
formed consent."
"This consent form contains detailed information about the
clinical research study which the person doing the research will
discuss with you. Once you understand the study, you will be
asked to sign this form if you agree to have your child take part
it. You will be given a copy of this form to keep as a record."
INVITATION TO PARTICIPATE IN STUDY
"You are being asked to consent to your child's participation in a
clinical research study called ." [insert title of re-
search study]
"The purpose of this study is _" [explain purpose, in
lay terms]
"You are being asked to consent to your child's participation be-
cause " [explain why subject is being recruited,
in lay terms]
"It is expected that there will be about [insert approxi-
mate number] persons taking part in this study." (If approximate
number of participants in unknown, delete the sentence).
DESCRIPTION OF THE RESEARCH STUDY
a) Give a concise description of the research protocol, in lay
terms. Include all tests and procedures to be performed, types
and amounts of radiation, medications to be given, special diets
to be followed, and so on. Describe any discomfort to be ex-
pected, and what will be done to minimize it.
b) Any experimental drugs, devices, or procedures must be
clearly identified as experimental. State whether a placebo or
randomization will be used, by following these examples.
Placebo statement: "In order to test the effectiveness of
your child will be selected to receive either
or a placebo (inactive compound), which will look the same
as the drug. Neither you, your child, nor your child's doc-
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tor will know which one your child is taking until after the
study, but this information will be available to your child's
doctor in an emergency."
Randomization statement: "Your child will be randomly
selected to receive one of two different treatment plans.
This is similar to a flip of a coin, and your child's chances of
receiving either treatment are about the same."
c) Explain whether the study involves inpatient or outpatient
care, and the expected duration of each. If there are contingen-
cies that will alter the duration of the study, these should be
noted.
Inpatient/outpatient statement: "Your child's doctors ex-
pect that your child will be in the hospital for about -
weeks, but he or she may need to stay longer. After that,
your child will be seen as an outpatient (in the office or
clinic) about once every - weeks for the next __
months."
POTENTIAL RISKS
a) Describe reasonably foreseeable risks, side effects, or discom-
forts, whether physical, psychological, or social, in lay terms.
Parents and patients should be warned that the underlying con-
dition may not improve, or may worsen, during participation.
b) If there is potential risk to a fetus, now or in the future, a
statement regarding the risks of pregnancy must be included.
The following are examples of fetal risk statements:
"The effects of [drug, device, or procedure] on an
unborn child are not known, and it is not known whether
[insert one: "taking this drug," "using this de-
vice," or "undergoing this procedure"] now can have effects
on unborn children in the future. If your daughter becomes
pregnant while participating in this research study, it may
be harmful to the unborn child. If your daughter does be-
come pregnant, you should contact one of the doctors in-
volved in this research study immediately."
Or: " [drug, device, or procedure] is known to
cause serious birth defects in unborn children. If your
daughter becomes pregnant while [insert one:
"taking this drug," "using this device," or "undergoing this
procedure"], it may be harmful to the unborn child. If you
daughter does become pregnant, you should contact one of
the doctors involved in this research study immediately."
POSSIBLE BENEFITS OF THE RESEARCH
a) Describe the possible benefits to the individual of participa-
tion in the study. When there are no anticipated benefits for the
individual, describe the potential benefits to science from the col-
lection of information.
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ALTERNATE PROCEDURES OR TREATMENTS
a) Describe alternate approaches, such as standard therapy (if
any), other experimental therapies (if any), similar therapy not
part of a research protocol (if possible), or no further therapy (if
appropriate to the condition).
PAYMENT FOR PARTICIPATION
a) State whether the participant will be paid or reimbursed. Ex-
plain whether the payment is contingent on completion of all or
part of the study.
Payment statement: "You will be paid for each blood sam-
ple that your child gives."
Or: "You will be paid after your child completes all the
tests in this study. If he or she completes only half the tests,
you will be paid only "
Unlike the first half of the form, the second half contained
mostly standardized language, with relatively few options for indi-
vidual variation:
PAYING THE COSTS OF THE RESEARCH
"You will be responsible for paying any hospital costs of your
child's participation in this research project. Hospital costs in-
clude items such as physician visits, drugs, tests, and procedures
while your child is a patient in the hospital."
"You will also be responsible for paying any outpatient costs of
your child's participation in the research. Outpatient costs in-
lude items such as physician fees, clinic visits, drugs, tests, and
procedures performed while your child is not a patient in the
hospital."
a) Use where appropriate: "You will be provided a written
list of procedures required because of the research study.
These are tests that would not be done as part of routine
medical care for your child's condition. Some of these pro-
cedures may result in added costs. One of the persons in
charge of the research will discuss these procedures and
their costs with you."
b) If any of the foregoing costs will be absorbed by someone
other than the patient's family, indicate these arrangements
and modify the preceding paragraphs.
"The costs mentioned above may or may not be covered by your
insurance. A financial representative of [the h]ospital is available
to help you regarding cost and payment. That person may be
reached at [the telephone number of the hospital's admission
office]."
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INJURY RESULTING FROM THE RESEARCH
"Your child might suffer some injury from participating in this
research. If injury occurs while your child is a patient in [the
h]ospital, the hospital will provide treatment for the injury."
"Injury may occur while your child is not a patient at [the
h]ospital. If this occurs, please be aware that [the h]ospital does
not provide emergency room care for outpatients. Therefore,
your child should be brought to the emergency facility nearest to
you. If additional treatment is needed, it will be available at [the
h]ospital."
"You may or may not be responsible for paying the costs of
treatment for injuries to your child that result from participating
in this research. For further information on this subject, please
contact the Quality Assurance/ Risk Management Department
of [the h]ospital, at [that department's telephone number]."
CONFIDENTIALITY
"Your child's research and hospital records will be kept confi-
dential. However, agents of the United States Food and Drug
Administration have the right to inspect the records of research
done at [the h]ospital. This includes the research involving your
child."
a) Use where appropriate: "Also, companies that provide
drugs or devices to be used in research frequently reserve
the right to inspect research records involving their prod-
ucts. In this research project agents of [insert
company name(s)] will have the right to inspect the research
records."
"The results of this research may be published. Published reports
will not include your child's name or any other information that
would identify your child."
VOLUNTARY PARTICIPATION
"Your decision to allow your child to participate in this research
must be completely voluntary. You are free to choose either to
let your child enter the research study or to keep your child out
of the study. There will not be any penalty or loss of benefits for
you or your child if you decide not to allow your child to
participate."
"Before you make your decision, one of the persons in charge of
the research will give you a chance to ask any questions you have
about the research study. Do not sign this form unless you have
had this chance to ask questions and have received satisfactory
answers to your questions."
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RIGHT TO WITHDRAW
"Even after agreeing to allow your child to take part in this re-
search, you may withdraw your child from the research at any
time. If you do decide to withdraw your child from the research,
there will be no penalty or loss of benefits for you or your child.
After withdrawal, your child will be offered available care that
suits your child's needs and medical condition. Before with-
drawing your child from this research, you should notify one of
the persons in charge of this research that you wish to withdraw.
This notice will allow that person or someone else supervising
the research to inform you if there are medical risks of
withdrawal."
NEW INFORMATION ARISING DURING THE
RESEARCH
"During a research project, new information regarding the risks
and benefits of the project may become known to the persons in
charge of the research. Also, they may get new information
about other possible treatment. If at any time during this re-
search project the persons in charge of it learn of any such new
information, they will tell you about this new information."
"New information may convince the persons in charge of this
research that it is not wise to continue the research. If this oc-
curs, the research project will be stopped. Or, the new informa-
tion may show that your child should no longer participate in the
research. If this occurs, the persons supervising the research will
stop your child's participation in it. In either case, your child
will be offered available care that suits your child's needs and
medical condition."
PERSONS TO CONTACT
"The persons in charge of this research are the investigator and
co-investigators listed on the first page of this form. Whenever
you have questions about this research project, you may contact
one of them at [daytime phone number, other than
[the hospital]'s general switchboard number] or [the hospital's
general switchboard number]."
"If you have questions about your rights as the parent of a re-
search participant, or about the rights of your child, you may
contact a representative of the Institutional Review Board of [the
h]ospital. That person can be reached at [the telephone number
of the hospital's IRB chairman].
At the close, to heighten the sense of the consent's importance,
the form switched from "you" to "I" in identifying the research
subject's parent:
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CONSENT
By signing this form I agree that:
1. I have fully read this informed consent form.
2. I have had the opportunity to question one of the persons in
charge of this research and have received satisfactory answers.
3. I have been given a copy of this informed consent form,
which is mine to keep.
4. I freely give my consent to have my child participate in the
research project outlined in this form, under the conditions indi-
cated in it.
Signature of Parent or Legal Guardian Date
Signature of Parent or Legal Guardian Date
Signature of Investigator Date
Signature of Witness Date
THIS RESEARCH PROJECT/STUDY HAS BEEN
REVIEWED BY THE ... HOSPITAL INSTITUTIONAL
REVIEW BOARD FOR THE PROTECTION OF HUMAN
SUBJECTS. 2 8
When the IRB finally adopted the form, I felt a sense of antici-
28. The form ended with the following addendum regarding the child's assent, see supra
note 27:
If possible, assent from the participating child should be obtained. The research
study should be explained to the child in words the child can understand, with a
parent and a witness present. The child will indicate assent by signing this form. If
the child's assent cannot be obtained, the reason should be listed on this form and
the parent and witness should acknowledge this reason by signing the form.
CHILD'S ASSENT
"I agree to be in the study explained to me by
[insert name of investigator or co-investigator giving explanation].
Signature of Child Date
Signature of Parent or Legal Guardian Date
Signature of Investigator Date
Signature of Witness Date
"1 [Insert name of child] is unable to give assent for the
following reason(s):
Signature of Parent or Legal Guardian
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max. In one way, the form's adoption was the culmination of all
the work I had done at the hospital, and I was quite proud of it.
But it was only a piece of paper-and an overwhelming bureau-
cratic one at that. My "accomplishment" would undoubtedly affect
the lives of those who did research at the hospital-and those on
whom research was done-but whether it would actually improve
anyone's lot was an open question.
Through the long gestation of the approved form, the principal
work of the IRB continued. One project, considered while I was
vacationing but deferred to a later meeting, particularly drew my
ire. The informed consent contained what was labeled a "HOLD
HARMLESS CLAUSE," purporting to waive the patient's right to
sue the hospital or any of the researchers, who were affiliates of the
hospital but not its employees. In urging the deletion of this clause,
I pointed out that the applicable federal regulations specifically
stated that nothing in an informed consent could limit the rights of
the research subject.29 The bland reaction of the physicians on the
board was that the researchers' malpractice insurer insisted on this
language. Because I would not take this for an answer, Dr. Figaro
deferred consideration of the project a second time.
In the interval between meetings, I had a number of twisted
thoughts about this matter. At one point, I considered dropping
my objection; leaving the ineffective language in would lull the in-
surance company into erroneously thinking it was protected-and
the eventual liability would serve them right for being so insistent.
But the same language might also convince a gullible (or principled)
patient that there was no legal recourse. Another solution I envi-
sioned was to put the waiver of rights in a separate document,
where the federal regulations regarding IRB informed consent
would not apply. But I was loath to help insurance companies fig-
ure out an effective way to get patients to waive their rights.
When the matter came up again, I registered my displeasure
with language so loud and long that Barbarina-who as chief finan-
cial officer did not attend the IRB meetings, but apparently read
their minutes-telephoned me about it. We had not talked at
Signature of Investigator Date
Signature of Witness Date
The model for this assent form was part of an informed consent submitted to the IRB by a
nurse studying the effects of music (administered by headphones) on the pulse, blood pres-
sure, and temperature of child patients.
29. See supra text accompanying note 10.
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length since I joined the IRB, and this conversation gave me the
chance to say that despite my occasional flareups (like the one that
occasioned her phone call), I greatly enjoyed my work on the board.
Another topic that occupied board time in the last half of 1989
was a research project involving "Escherichia coli replacement ther-
apy in the treatment of chronic inflammatory bowel disease." The
project required patients first to submit to complete obliteration of
bacteria in the intestinal tract (by antibiotics) and then to effect
their replacement by drinking a solution containing new bacteria.
Asking research subjects to "drink shit," as one board member put
it, was more than most of the IRB was willing to do. The board
deferred the project the first time it came up. At the next meeting
the physician who was most interested in the project came to dis-
cuss it-still a relatively rare event-and brought with him a bottle
of the solution, offering to drink it himself. Even this did not con-
vince the board, which continued to express many reservations
about the project-which ultimately was withdrawn.
The attitude of board members to this doctor surprised me. He
and his research drew snickers, and they were not entirely caused
by the bizarre nature of his project. For some reason, unknown to
me, he was not quite worthy of the respect and deference the IRB
members usually showed their colleagues. I thought of similar re-
sponses I had seen from my law school colleagues-humoring those
professors with a reputation for competence, while making life hard
for those with the opposite reputation-and wondered if the com-
parison was apt.
Another example of this apparent disparity was the solicitude
with which the IRB had treated Dr. Selim. It was the latter half of
1989 before the board finally received from Selim informed consents
drafted by someone on his staff, rather than by the national consor-
tium of pediatric oncologists. Selim's staff member Papagena was
responsible for this change, and the rest of the board was so happy
that we thanked her profusely and overlooked the few deficiencies
the forms still contained.
Still behind in its work, the IRB met twice in August 1989 (in
addition to subcommittee meetings, major and minor). One and a
half to two hours continued to be the typical meeting length, but
some members were oblivious to the need to keep the agenda mov-
ing. Dr. Ferrando in particular tended to drone on and on in his
lilting accent, focusing on minute problems in the research protocol
and the informed consent; he gave thoroughness a bad name.
At one meeting in late 1989 Ferrando and his subcommittee
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members, Despina and Zerlina, were particularly exhaustive. They
directed most of their attention at one of Dr. Alfonso's projects,
taxing him for (among other things) using informed consent lan-
guage that was too difficult in some spots and too superficial in
others. Alfonso did not take the criticism well, and began to sputter
about the futility of trying to explain complicated medical proce-
dures in a few pages of very simple prose.
Of course, I had heard this from Dr. Alfonso before. But it had
new meaning for me that day, because I thought that the subcom-
mittee members were going too far, that they were asking research-
ers to do more than was necessary. For the first time I wondered if
my harping on informed consent for all these months had created a
monster.
What was to be my final year on the IRB opened in typical fash-
ion, with the introduction of new members. Zerlina had taken a
risk management job at another hospital in the area (as she left her
last meeting she told me that I had "made a difference"; it is the
accolade of my board membership that I most prize). Her replace-
ment was Blonde, another risk manager. Because new construction
at the hospital had allowed staff expansion, Reverend Nettuno had
a new assistant, to whom Nettuno surrendered his IRB position.
The assistant chaplain participated diligently in the board meetings,
but he never seemed to get the hang of it. (Six months later the
hospital psychologist followed the lead of the chaplain. The psy-
chologist's assistant, a quiet woman with alert eyes, was less active
than the assistant chaplain, but seemed to understand more of what
was going on.)
There were two new nurses, whom I never really got to know,
and two new physicians, only one of whom regularly attended meet-
ings: Dr. Guglielmo, a young pulmonary specialist, who quickly fell
into step with his friends, Drs. Susanna, Almaviva, and Ferrando.
The other new health professional who became an IRB regular was
Dr. Osmin, a researcher with a Ph. D. but not an M.D., whose
husband was the chief physician-in-charge at the hospital.
Dr. Osmin was a veteran of research projects at the university
hospital, and frequently criticized those aspects of our IRB process
that were inconsistent with the university IRB's procedures. For
example, she complained about the length of our meetings, saying
they would be shorter if we would insist on attendance by one of the
investigators on each project (as the university did). My thought
was exactly the opposite: Whenever we had one of the investigators
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in the room, the process of explanation and defense inevitably
lengthened the meeting.
Dr. Osmin's emphasis on the university IRB was ironic, because
during that same time period former patients at a university-affili-
ated hospital sued the university (among others), alleging inade-
quate informed consent prior to research.3 0 The lawyer filing the
complaint was reputable, so I copied a few newspaper articles about
it and circulated them to board members. At a subsequent meeting
Dr. Susanna wondered aloud why we should consider following the
example of a board whose oversight of informed consent was the
subject of a lawsuit.
To tell the truth, Dr. Susanna and I had another reason for
wanting to diminish the authority of the university IRB among our
board colleagues. Because so many of the hospital's doctors did
research at the university as well, the approval of the draft informed
consent, on which she and I had worked so hard, remained contin-
gent on our form jibing with the requirements of the university. We
feared that the university IRB, sensing a turf battle, would demand
something different from our form, and thus undo all our previous
effort.
Thus it was a great relief to learn that the head of the university
IRB, to whom Dr. Figaro had sent our form for comment, had only
a few, relatively minor suggestions for change. I revised the form to
reflect most of these changes, which the board approved in Febru-
ary 1990. But a few months later Figaro announced that the head
of the university IRB had not realized that she was "officially" com-
menting on our form-she thought we were merely interested in her
personal opinion-so the issue of conformity between the two
boards remained unresolved (and still does, as far as I know).
Thinking that the informed consent form had cleared its final
hurdle, the IRB set about the task of enforcing its adoption. It was
relatively easy to require that new research projects adhere to the
form, but the considerable number of project renewals proved much
more vexing. Researchers complained that having to extensively re-
vise existing informed consents was a colossal (and often point-
less"1) burden, and frequently sought temporary "reprieves" from
the requirement. For example, Dr. Alfonso- whose informed con-
30. Part of the alleged inadequacy in the informed consent was the lack of forms in
Spanish. See supra note 6 and infra note 33.
31. Frequently, research projects continued with existing patients, and thus required
regular review, but were not open to new patients, so that revising the informed consent was
arguably unnecessary.
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sents continued to use phrases like "high-grade encapsulated bacte-
rial pathogens," "semi-permanent catheter," and "pre-transplant
preparative regimen"-was a frequent requester of reprieves.
Dr. Selim had found another way of dealing with the new form.
Apparently, he assigned two secretaries to translate, with the help
of Papagena, the pediatric cancer consortium's informed consents
into the hospital's form. Whenever Selim had an item before the
IRB-virtually every month-the two secretaries would attend and
dutifully jot down our many suggestions for changes.
Physicians who had neither Alfonso's temerity nor Selim's man-
power found a third way of dealing with the requirement: They
simply ignored the IRB. One month Dr. Figaro reported that he
had earlier notified the investigators on thirty-four projects that
their requests for review were overdue (some by as much as a year);
however, over two months later, only seven had replied. Equally as
alarming was the fact that the IRB had no mechanism for assuring
compliance with its suggestions when a project was "approved, with
changes"-which had become our usual disposition, with the
changes usually in the informed consent. For all we knew, re-
searchers were ignoring our indicated amendments.32
The board's concern regarding these matters heightened when
we received another opinion letter from outside counsel, again from
Cherubino. Quality Assurance had asked, among other things,33
whether the hospital and its researchers might be liable for research
pursued with lapsed IRB approval. Cherubino's answer (once one
waded through a thicket of statute and regulation recitations) was
an emphatic yes.34 (I wondered whether individual IRB members
might also be liable; I doubt I was the only board member who
considered this question.) Cherubino's letter probably contributed
to the hospital's decision to hire a full-time secretary for the IRB,
one of whose responsibilities was to "bird dog" projects through the
application and renewal processes.
32. Or they were ignoring the protocols the IRB had approved. At one meeting during
1989 or 1990, one physician on the IR apologized because a patient in one of his projects
had received drug therapy for many days beyond the maximum indicated in the research
protocol. Except for self-reporting such as this, the board had no way of knowing when such
deviations occurred.
33. The hospital also wanted to know whether it was required to provide written trans-
lations of informed consents for patients who did not understand English. See supra notes 6
& 30. Cherubino indicated that a written translation was legally preferable to using an inter-
preter, the hospital's usual way of dealing with the problem.
34. Dr. Figaro later told me that he had golfed with Cherubino soon after the hospital
had received his letter; Cherubino had laughingly told Figaro that he loved to write letters to
the hospital, especially for fees in the four-figure range.
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When researchers did use the new form, a few problems quickly
appeared. Some physicians slavishly copied the form-down to its
quotation marks and interlinear instructions to researchers, which
were never intended for the final product. Others poked fun at the
form's relentless emphasis on lay language. After his reprieves ran
out, Dr. Alfonso submitted an informed consent that began:
The sickness that the doctors call "severe combined immuno-
logic deficiency disease" (SCID) has been found to be due to the
baby's being born with no way to kill bad germs. For this rea-
son, the baby is puny and will have lots of bad infections. If the
baby is not treated right, the chances are that the baby will die
from a bad infection during the first year of life. There is more
than one kind of SCID, but babies with all kinds of SCID can't
fight bad germs. They have poor immunity. This poor immunity
is due to the thymus gland's not working right. The thymus
gland is in the chest and certain white blood cells called, "T-
cells," go through the thymus gland to be able to fight bad germs.
Though not quite so classic a putdown, the rest of the informed
consent continued in approximately this fashion (e.g., "Research is
the way in which scientists try to find out new things.").
When I first read this offering, my inclination was to be angry. I
felt what another IRB member said at the meeting: "I think we're
being made fun of." But when I had cooled a bit, I considered the
ridicule somewhat justified, and more important, it had produced a
more easily comprehensible document-even if that was not Al-
fonso's primary intent. As I recall, the board approved the in-
formed consent with few changes.
Beside causing problems for the researchers who used it, the
new form caused problems for some IRB members. One difficulty
to which I fell prey was skimming through sections that I assumed
were copied directly from the form, and thus running the risk of
missing a variation. At one meeting, after my superficial discussion
of a project assigned to my subcommittee, Dr. Susanna politely
asked what I thought of the change in the "Paying the Costs of the
Research" section. As I looked at the section and noticed the dis-
parity for the first time, I considered trying to bluff my way through
my oversight. But I quickly decided that truth would be more in-
structive-and I probably could not have pulled off the bluff any-
way. So I confessed my error and then segued into a pious
discourse on the ease of missing something crucial in the informed
consents.
Another problem that the form posed for the IRB arose when
its provisions seemed inapplicable to the specific research under
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consideration. For example, for research that involved only a tele-
phone survey and a blood sample, some board members thought
that it was silly to include in the informed consent language regard-
ing the costs of inpatient and outpatient treatment. Such costs were
not possible, or so the argument ran, and therefore the language was
irrelevant. I found myself resisting this contention, but for no good
reason, other than maintaining the integrity of the form: If a devia-
tion from the form was allowed in this case, it made it that much
easier to argue for a deviation in a less appropriate situation. But
the inflexible conservatism of this view shocked me, and I guessed
that my main motivation was a simple desire to protect my work
product from any attack, justified or not.
As 1990 progressed, the IRB meetings again began to lengthen.
After relatively short agendas at the beginning of the year, there
were twenty items on the agenda in April, twenty-six in May,
twenty-eight in June, and twenty-seven in July. Most of the addi-
tional items were Dr. Selim's projects from the national consortium
of pediatric oncologists. Though Selim's informed consents now
followed the prescribed form, they still had a number of defects.
Many were inordinately complicated, with different options among
alternating courses of chemotherapy and radiation, sometimes ex-
tending over years; the side effects of the various drugs usually took
pages to describe. A minor defect, but one that got on my nerves,
was the look of Dr. Selim's informed consents: Until I complained,
his forms invariably came to us looking like fifth generation copies
of poorly printed documents. Beside being difficult to read, they
said to all who saw them-including patients-"This is not an im-
portant piece of paper."
Though the IRB was going through its share of difficulties, I felt
that it had reached a plateau. There was a core membership-
Figaro, Susanna, Almaviva, Ferrando, Despina, Papagena, and I-
with a clear vision of the mission of the IRB: to use informed con-
sent to protect the rights of patients. A slightly larger group-Otta-
vio, Titus, Figaro's father, Pedrillo, and Guglielmo and virtually all
the other new members-shared that vision, if somewhat less
clearly. Even the board's holdouts-Alfonso, Osmin, Basilio, and
Blonde-occasionally subjected research projects and their in-
formed consents to the close scrutiny I thought was necessary.
With the administrative support of a full-time secretary, who first
appeared at the August 1990 meeting, the IRB was on the verge of
becoming a potent force in the hospital.
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August was also the occasion of my service on yet another sub-
committee. Two months earlier, in considering a project that in-
volved research on excised tumors, Dr. Titus had questioned
whether the patient would retain any interest in the "cell lines" that
such research might produce. The IRB had discussed this issue
before,35 and I finally saw its relevance to the discarded tonsil re-
search that the board had considered at my very first meeting36:
Marketing medical products developed from removed body parts
could be quite lucrative, and the patient at least should know
whether he has any interest in such a product. I offered to look into
the legal question and report back to the IRB.
After some perfunctory research, I circulated a short memo,
suggesting that the following language be added to the informed
consent form, under "PAYMENT FOR PARTICIPATION":
"Add where appropriate: 'Tissues taken from you, including blood
and other fluid samples, may be used in the creation of new medical
products. You may or may not have a financial interest in any such
product.'" While the rest of the board was considering this lan-
guage, the California decision that had sparked the first discussion
of the issue was modified on appeal. Though the California
Supreme Court rejected the research subject's claim that he had a
property interest in any product made from his body parts, the
court did hold that the researchers had a "fiduciary duty" to inform
the patient of any financial interest the researchers would have in
such potential products. 38 Dr. Figaro's father and I both circulated
newspaper accounts of the decision. Though this out-of-state deci-
sion was not binding on the hospital, the case did seem to under-
score the need for some reference to the problem in an informed
consent.
The issue, and my proposed resolution of it, apparently caused a
stir at the hospital sufficient for Dr. Figaro to ask Dr. Susanna and
me to meet with two hospital physicians interested in the question.
This subcommittee met in August, just before the scheduled IRB
meeting. Blonde also attended the meeting, as a representative of
Quality Assurance/Risk Management.
The interested doctors, one of whom was new to the hospital
and reportedly quite eminent in his field, initially resisted any no-
35. See supra text accompanying note 18.
36. See supra text following note 7.
37. Moore v. Regents of the Univ. of Cal., 793 P.2d 479 (Cal. 1990). See supra text
accompanying note 18.
38. Id. at 485.
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tion of informing patients that their discarded body parts might be
valuable. But they did not understand that Susanna and I were
talking about including such information only in research-related
informed consents. Their main concerns, it appeared, involved
other hospital documents-the general medical treatment consent
form and the consent for autopsy, for examples. Though Susanna
probably agreed with me that these documents ought to contain
similar information, that issue was beyond the bailiwick of the IRB,
and we did not pursue it. (I did wonder why these doctors were so
interested in the question; was it an aversion to increased
paperwork, or something more?)
With their concerns satisfied, the physicians helped Susanna and
me redraft the language, producing: "Tissues taken from you, in-
cluding blood and other fluid samples[,] may be used in the making
of new medical products. The persons conducting this research
do/do not have a financial interest in any such product. You may
or may not be entitled to receive profits from this product." In Oc-
tober (after a deferral from the September meeting, because of an-
other long agenda), the IRB voted to add this language to the
informed consent form.
Another topic before the board in October 1990 was AIDS.
Several of the research projects at the hospital involved aspects of
treatment for acquired immune deficiency syndrome,39 but the pro-
ject up for consideration in October, from Dr. Selim, dealt instead
with transmission of the AIDS virus. The project required comple-
tion of questionnaires by and blood tests on hemophiliacs and their
household members; the questionnaires included detailed inquiries
about sexual practices.
Board members had two separate questions. First, if the blood
tests revealed that a patient was HIV-positive, would the hospital be
under any legal compulsion to report that information to public
health officials-and if it was, should that be mentioned in the in-
formed consent (which said only that the research subject's "confi-
dentiality will be protected to the fullest extent allowed by law")?
Second, would a parent's consent to participate in the research bind
a sexually mature child-and would the parent be able to see the
child's answers, especially those relating to sex acts?
39. For example, earlier in 1990 the board had considered a project from Dr. Alfonso
for pediatric AIDS patients who had not responded to treatment with AZT. The IRB ap-
proved the project, but only after insisting that the informed consent use the term "AIDS,"
rather than euphemistically referring to use of an "antiretroviral drug because your child has
experienced substantial deterioration despite AZT treatment."
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The IRB deferred consideration while both questions were in-
vestigated. The first was a straightforward question of law, and as
a new member of my county's "AIDS Coordinating Council," I had
access to materials that gave a quick answer: Under state statutes,
the hospital had to report cases of full-blown AIDS to state public
health officials, but not mere instances of HIV-positivity. The sec-
ond question really asked when it was necessary, legally and ethi-
cally, to get the child's agreement. The board had frequently
discussed this matter, and had made decisions as far as individual
projects were concerned, but had never adopted an across-the-board
policy.4°
At the November meeting the IRB accepted the "fullest extent
allowed by law" confidentiality language (though its opacity and
open-endedness bothered some of us), and determined that assent
by children over thirteen was necessary, in addition to their parents'
consent. We also agreed that a child's responses would be kept con-
fidential, even from the child's parents. There was no real effort to
develop a comprehensive policy on child assent; perhaps case-by-
case decisionmaking was the best method of dealing with the
problem.
Curiously enough, another research project on the November
1990 agenda raised roughly similar issues. Dr. Monostratos, whose
name meant nothing to me, assisted by Dr. Osmin and Dr. Osmin's
husband, wanted to compare the "immunological competency" of
babies born to cocaine-addicted mothers with those born to nonad-
dicted mothers, through analysis of blood samples taken at birth,
three months, and six months. As in the study of AIDS transmis-
sion, this research raised questions of mandatory reporting and con-
fidentiality. The hospital was legally required to report any
newborn whose blood tests disclosed a controlled substance, so par-
ticipation in the study could expose the mother to criminal prosecu-
tion 4 -a fact that I thought should be considered in evaluating the
research project and the confidentiality section of its informed
consent.
Other IRB members had a different concern. With unusual cir-
40. See supra note 27.
41. In 1990 an appellate court in one state had upheld the conviction of a mother for
delivering a controlled substance to her child, through the umbilical cord. Johnson v. State,
578 So. 2d 419 (Fla. Dist. Ct. App. 1990). Similar prosecutions were pending in other states.
See generally Rachel M. Nicholson, Note, No (Pregnant) Woman Is an Island: The Case for a
Carefully Delimited Use of Criminal Sanctions to Enforce Gestational Responsibility, 1
HEALTH MATRIX 101 (1991).
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cumspection, a few board members pointed out that the research
protocol was sketchy about how the researchers were going to de-
termine which mothers were "addicted"; the mere presence of co-
caine in the mother's or child's bloodstream would not necessarily
evidence addiction. Because she was not the principal investigator,
Dr. Osmin could not clarify this obscurity, which I saw as a "gar-
bage in, garbage out" problem: Without a clear definition of addic-
tion, the study would prove little-all the while exposing its
participants to possible criminal sanctions. The IRB deferred con-
sideration of the project so that Dr. Monostratos could define what
she meant by addiction.
A third item of interest on the November agenda was a seem-
ingly innocuous project that involved cardiac catheterization at the
hospital of patients who had received an experimental drug at an-
other area hospital. Figaro had given the project preliminary ap-
proval under expedited review, but Basilio was apparently upset
that the researcher (who was not a hospital "regular") had not got-
ten administrative clearance as well. When Basilio said some things
about the hospital's trustees being the ultimate decisionmaker and
how the IRB just made recommendations to the trustees, I spoke
up. Of course the hospital, through its trustees, could decide not to
implement a research project approved by the IRB-the outcome
Basilio was recommending for this project. But the trustees could
not legally decide to implement a project the IRB had disapproved;
in this respect, I lectured him, the federal regulations controlling
research with human subjects made the IRB superior to the hospi-
tal's trustees. Basilio professed shock at this assertion.
I knew that the last half of my comment was irrelevant to the
project before the board, but I wanted to upset Basilio's smug asser-
tion of administrative authority. At the time, my rationalization
was that I did not want to let Basilio go uncorrected, in order to
avoid setting some sort of precedent-even though precedent sel-
dom commanded much respect at the IRB. Despite my outburst,
Dr. Figaro and others were able to paper over the dispute, by sim-
ply approving the proposed project and letting the hospital adminis-
tration decide whether the research would ever actually be carried
out.
As I prepared for the December 1990 board meeting (which was
to be my last), I thought that perhaps I should try to mend fences
with Basilio, whose job after all made a hierarchical, bureaucratic
perspective unavoidable. However, the agenda for the meeting of-
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fered little controversy (and therefore little opportunity for
solidarizing with anyone). The agenda did have a curious cover
sheet, with a bare-bones outline of the meeting, "Happy Holidays"
in large ornate Christmas script, and the following at the bottom:
"All information discussed at the Institutional Review Board Meet-
ing is confidential and information shall be shared only with those
professionals who are involved with the Board." I wondered where
that came from.
Among the first to arrive for the December meeting, I made
polite chit-chat as the members straggled in. When Dr. Susanna
entered, she threw her packet on the conference table in disgust.
Susanna was never one to keep her dissatisfaction bottled up, and I
assumed she had had another trying day at the hospital. From
across the room I said something to her like "That bad?," and she
turned to me and responded, "Haven't you heard?" I did not un-
derstand her response and was mumbling something as Dr. Figaro
entered the room.
Figaro quickly began the meeting by announcing that we would
not be covering the agenda today, as some other matters had come
up. Specifically, he had been informed by the hospital's incoming
chief of staff-Dr. Monostratos-that she was unhappy with the
IRB's performance, especially the length of its meetings, that begin-
ning in January the IRB would have a new chairman, and that
while the new chairman would come from the ranks of the current
board members, a large number of the other members would be
new.
Some board members, like Dr. Susanna and Basilio, were not
surprised by these announcements (though my guess is that they
had received advance word from different sources). But most of us
were shocked. There followed a few minutes of incredulous ques-
tions, during which Dr. Figaro maintained an air of restrained an-
ger and disappointment; as an example of his restraint, he
specifically refused to indicate who the new chairman would be,
though he clearly knew the name.
The vast majority of those present were unhappy with the
wholesale replacement of the board. (Those who were not unhappy
were keeping their own counsel.) While we all had better things to
do with the time we devoted to IRB work, no one liked being
dumped so unceremoniously. At one point Dr. Guglielmo face-
tiously suggested that we reconsider Dr. Monostratos' research pro-
ject. Not in a facetious mood, Dr. Figaro observed that those who
wanted to register their disagreement with the action should draft
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and sign a joint letter of protest to the hospital's board of trustees.
Several members, including me, agreed to participate.
At the close of the meeting, Blonde reminded us that IRB pro-
ceedings were confidential (answering my question about the
agenda coversheet). After the meeting, Basilio remained talking to
several hangers-back, including Figaro, Susanna, Blonde, and me.
Basilio was being very conciliatory, saying that there had been some
sort of terrible misunderstanding. When I learned (from Dr.
Susanna, who was talking to Blonde and me) that Dr. Monostratos
was responsible for appointing only the physician members of the
board, and that Basilio appointed the other members, including me,
I moved into his knot of conversation and said that I very much
wanted to continue my membership. He responded that for the
sake of continuity, I should stay on the board. As I left the hospi-
tal, I thought it was ironic that Basilio, whom I had abused so re-
cently, would be the one to save my position on the IRB.
Over the next few days I had many telephone conversations: one
with Barbarina (who expressed the same sort of solicitude as Basi-
lio); several with the IRB secretary, who was acting as the main
contact person, through the hospital fax machine, regarding the let-
ter of protest (worried, I told her to be careful not to get fired); and
one with Figaro (who decided, for security reasons, that I should
fax my edit of the draft letter to his private office, rather than to the
hospital). Over the phone, Figaro seemed in something of a funk,
which I thought-but did not say-he should snap out of; after all,
his fall as the hospital's IRB chairman was not the end of the world.
From one of these calls I learned that Dr. Titus had originally
agreed to chair the board in the coming year, but had withdrawn
his agreement in light of the furor at the hospital over Dr. Monos-
tratos' actions. This fact was confirmed to me by Monostratos her-
self, in a very curious telephone conversation. One day, out of the
blue, she called me at my office, saying that we should talk. Over
the phone, she portrayed herself as surprised by complaints that she
was exercising her power to appoint new IRB members. She said
that this unexpected outburst was forcing her to take over the board
chairmanship herself, a task she really had no time for. She consid-
ered the letter of protest (which had not yet been mailed) as an act
designed to subvert her rightful authority. Her conclusion was that
she did not think that she could work with me on the IRB.
Perhaps she was trying to get me not to sign the letter, in order
to save my position on the board. But the offer was not that clear, I
really could not break my promise to Figaro or Susanna, and be-
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sides, I had Basilio's implied commitment to retain me. So I told
Dr. Monostratos that she should withhold judgment on the letter
until she had read it, and that I stood ready to work with her and
anyone else on the incoming IRB. Later that day I called Basilio,
giving him the gist of my conversation with Monostratos (he was
surprised to learn that she planned to chair the IRB) and reiterating
my willingness to work with her and the new board.
Five days after the December meeting the letter of protest was
mailed to Dr. Monostratos. It read as follows:
We, the members of the [h]ospital Institutional Review Board,
have a number of concerns regarding the recently proposed
changes in the leadership and membership of the committee.
As you know, the IRB is charged with the responsibility of re-
viewing all protocols involving research at [the h]ospital. Ac-
cording to the federal mandate for IRBs, this review focuses on
the protection of the rights of research subjects and thus is espe-
cially directed at the process of informed consent. Also, the "sci-
ence" of each study is reviewed to ensure that any potential risks
to subjects are outweighed by the information or potential bene-
fits to be derived from the study.
As you may be aware, the number and complexity of the proto-
cols submitted to the IRB for review over the past few years has
grown exponentially. Membership on the committee has also
grown to meet this ever increasing demand. Under Dr.
[Figaro]'s leadership, the IRB has developed a subcommittee sys-
ten designed to enhance the organization and efficiency of the
committee. This subcommittee system has succeeded primarily
because the committee members have confidence in each other's
high standards of critical review, allowing for a streamlined yet
thorough review of each of the many protocols submitted. In
this way, the investigators and research subjects all benefit.
It is our understanding that the criticisms of the current IRB
include the following:
1. Length of IRB meetings.
2. Investigators are not invited to meetings.
3. [P]rotocols [from the consortium of pediatric oncologists]
should be handled by a subcommittee.
We are concerned that none of these criticisms had been brought
to the attention of the IRB chairman or committee members
prior to our being informed of the proposed changes in leader-
ship. In answer to some of the above concerns, we would like to
advise you of the following:
1. The meetings are held monthly and generally last 2 hours,
although some may last longer. Most of the members stay
the entire length of the meeting, which indicates that we are
committed to our work on the IRB and do not have a serious
concern about meeting times.
2. Whereas individual principal investigators are not generally
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invited to attend IRB meetings, they are usually well repre-
sented by the members of the IRB, who often are co-investi-
gators in the protocols submitted. When this is not the case,
investigators have been invited to discuss their projects at
IRB meetings. Additionally, designated representatives for
the [consortium] protocols routinely attend IRB meetings to
facilitate review and revision of [consortium] protocols.
3. As already mentioned, protocols are reviewed by a subcom-
mittee of three IRB members and then presented to the en-
tire committee for further discussion. This holds true for the
[consortium] protocols, which are generally reviewed by the
same subcommittees, who have developed a degree of flu-
ency with these complex projects. Again, this was instituted
in order to enhance the efficiency of the IRB's work, and to
facilitate the work of the [consortium] investigator.
Given these facts, we believe there is no rational or logical basis
for the proposed sudden changes in IRB membership or leader-
ship. If there were substance to our alleged inadequacies, we be-
lieve they should have been brought to the attention of the
committee and that we should have been given the opportunity
to discuss them and make any necessary changes. We are con-
cerned that the proposed changes to our committee would be a
disservice to the institution, the investigators, and above all, to
the patients we serve.
We strongly urge you to reconsider any changes in the member-
ship or leadership of the Institutional Review Board at this time.
Any of us would be happy to discuss with you any further con-
cerns you may have.
Copies of the letter went to the hospital's president, board of trust-
ees, and medical staff executive committee, and to Basilio.
Only six IRB members signed the letter, five physicians and me.
(According to Figaro, pressure was brought to bear on some of the
other nonphysicians on the board, each of whom was an employee
of the hospital.) Along with the expected signatures-Drs. Figaro,
Susanna, Almaviva, and Guglielmo-I found one that was totally
unexpected: Dr. Alfonso. And I was sad to see Dr. Ottavio's name
missing from the list.42
A few days after the letter of protest was mailed, I left town for
Christmas vacation. On returning after New Year's, I found in my
campus mailbox a brief letter of thanks from Dr. Figaro, apparently
sent to every member of the IRB.43 There was nothing else in my
42. At first sight of the letter I was surprised that Dr. Ferrando's name was missing, but
later I recalled that he was a junior member of Dr. Monostratos' hospital practice group.
There may have been an analogous reason for Dr. Alfonso's signature: Figaro was a junior
member of Alfonso's practice group.
43. I would like to extend my sincere thank you for the long hours you have spent
serving on the Institutional Review Board at [the h]ospital.
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mail regarding the IRB: no packet for the January meeting, and no
letter indicating definitively whether I was still on the board.
As it was uncommon for the hospital to send reappointment let-
ters, I was in some doubt about my status. So I called the IRB
secretary, who informed me, in her best attempt at a cheery voice,
that I was no longer a board member and that I would soon be
receiving an explanatory letter from Dr. Monostratos. The letter,
dated January 4th, arrived the next day:
This letter is in reply to yours of 12/17/90. I appreciate your
concerns over the proposed changes in the format and member-
ship of the Institutional Review Board. I have likewise been con-
cerned about the many negative comments which I have received
regarding this Committee. Scientists at this institution have com-
plained that it may take over 6 months to have a protocol ap-
proved. Investigators on the faculty of the [u]niversity ... must
also have their protocols approved by the University's IRB. This
can only be done after a letter of approval is received from the
[hospital] IRB. Therefore, there may be up to a one year delay in
implementing some protocols. The Committee has been de-
scribed to me as cumbersome and obstructive to research. Some
investigators have stated that they choose not to initiate research
projects or participate in nationwide studies at [the hospital] be-
cause of difficulty and delays in dealing with the IRB. In addi-
tion to these concerns voiced by investigators, I have some
concerns about the format of the Committee.
My concerns about the length of meeting times are two. One is
that meetings which last over 1 - 1 1/2 hours consistently usually
are trying to cover too much material. The possibility of sub-
committee or more frequent meetings should be considered in
such a case. My other concern is that the Committee members
have advised me that much of the meeting time is spent re-writ-
ing Informed Consent forms. Frequently there were lengthy dis-
cussions regarding simple changes in wording.
Invitation of principal investigators to IRB meetings is a com-
mon courtesy and expedites review of protocols. Co-investiga-
tors are not always aware of every aspect of the protocol and
therefore may not be able to answer every question raised. It is
unfair to the researcher to have the final decision on a protocol
delayed because he/she was not invited to a meeting to answer
all questions.
The [national cancer consortium] protocols are a specialized
The most important ingredient for any of our committees is the caliber and dedica-
tion of the individuals who give of their time. I view the efforts of each individual
committee member as critically important to the successful functioning of the Insti-
tutional Review Board.
I hope you have a wonderful Holiday and a Happy New Year.
Thank you again for your participation.
The letter was dated December 26th.
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group of national protocols. These protocols have been exten-
sively reviewed for scientific merit on a national level. Therefore
they do not require the same type of review as other protocols. A
true sub-committee (not a project review committee) could be set
up to evaluate these protocols separately from the main IRB
meeting. The minutes of this sub-committee meeting would then
be presented to the full Committee.
As past Chairman of the Committee for Human Values and Eth-
ics, I am well aware of the need for the Informed Consent. This
should be the case not only for patients involved in research pro-
tocols but also for any patient receiving treatments at [the
h]ospital. A research protocol is made up of more than an in-
formed consent. I feel that it is also important to have the scien-
tific value of every protocol evaluated. The skill to do this type
of evaluation does not come with a medical school diploma, it
usually requires graduate school or post doctoral research experi-
ence. Therefore, most physician members appointed to the Com-
mittee for the next year have such experience. The informed
consent forms will continue to receive intense scrutiny with more
lay input in the wording of these forms.
As past Chairman (1981-1985) and founder of the IRB at [the
h]ospital, I am well aware of the duties and responsibilities of
this Committee. Based on the information provided, major
changes in the format and direction of the IRB seemed indicated.
I felt this would most easily be accomplished by a change in
Chairman and membership. The anger and lack of critical self
evaluation reflected in your letter appear to make this a wise
decision.
As Chief of Staff for 1991 I have the responsibility for the actions
of this and other committees. The Hospital Bylaws state that the
Chief of Staff is "accountable to the Board of Trustees in con-
junction with the Executive Committee for the quality and effi-
ciency of clinical services and performance within the
hospital.. .". Given this responsibility, it is only appropriate that
the Chief of Staff has the right to appoint committee chairmen
and members. It can also be noted in the Rules and Regulations
of the Hospital that terms of committee membership for physi-
cians are for one year. Your attempt to undermine the authority
of the position of Chief of Staff is based entirely on conjecture
and speculation. The implication that the IRB will be unable to
function in your absence is both illogical and presumptuous. The
IRB is not the only committee for which I have recommended
major or minor changes for this year. However, it is the only
committee which has responded to such recommendations in the
manner which you have chosen.
My decision to restructure the IRB was made only after a great
deal of thought and discussion with many people. Therefore, I
have no plans to change my decision. If you had requested, I
would have been happy to have discussed this matter with you.
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According to Dr. Figaro, there is a sign on Dr. Monostratos' desk
that says, "I don't get mad, I get even."
Monostratos had sent copies of her letter to all those we had
copied with our letter, including Basilio. Still supposing that he had
control over my situation, I telephoned Basilio. His tone was still
conciliatory, but he denied having any authority over the question
of my reappointment. He laid all responsibility at Dr. Monostratos'
feet, saying that she had even recruited a new attorney member
(whose name I never learned).
That day I also called Barbarina. As in our conversation just
after the December meeting, she expressed respect for Dr. Monos-
tratos' skill as a physician but some doubts about the way she was
handling the wholesale change in IRB membership. (Beside Dr.
Titus, only one other previous member was retained; I never
learned who it was.) My call to Barbarina ended with her saying
that she had the ear of the hospital president, and I inferred that she
was planning to speak to him about my situation. I do not know
whether she did, because that conversation was the last contact I
ever had with any administrator at the hospital.
Now it was my turn to be in a funk. I was angry that the hospi-
tal had discarded me in so cavalier a fashion, and longed for some
sort of revenge. I took the language of Dr. Monostratos' letter and
mentally elaborated it into a coup d'etat by the hospital's research-
ers, who would now merrily go about putting patients at risk.
Someone should be warned of this, I thought, and I began drafting
in my head a letter to the Food and Drug Administration. Over a
few days this plan for vendetta developed a new aspect: I would
also release the letter to the local newspapers, which surely would
be interested in this power grab by physicians in high places.
It was Dr. Figaro who brought me to my senses. When I called
him-to get the name and address of the proper federal official to
contact-he suggested that a letter to the FDA would accomplish
little, other than making Dr. Monostratos angry, and thus running
the risk that she would lash out at the former IRB members at the
hospital. Of course he was right, I told him-I was trying to make
a mountain out of a very small molehill-and then I shifted the
conversation into general ruminations about our time on the IRB. I
carried this on for too long, and Figaro ended the conversation with
an abrupt "Take care!" His curtness stung a bit, but I quickly real-
ized that he was right about that too: It was time for both of us to
close this minor chapter in our lives.
A month or so later I ran into Dr. Titus at the intermission of a
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concert. After we traded appreciative comments about the orches-
tra, I mentioned the IRB, forcing him to discuss it. As I expected
him to, he apologized about "the way things were done" and the
misconceptions that some people had had about the board's work.
Then he paused, gave me his sad smile, and added: "You know, the
meetings take just as long."
I waited six months to begin writing this memoir, primarily be-
cause I wanted to overcome as much of my vindictiveness as possi-
ble. My feelings toward my work on an institutional review board
are now quite ambivalent. I understand better, and appreciate
more, the overt criticisms of Drs. Alfonso, Osmin, and Monos-
tratos, and the implicit criticisms of Dr. Selim. And I am less con-
vinced of the paramount importance of informed consent, in which
I, Drs. Figaro and Susanna, and many others so fervently believed.
I remain impressed with all the health care professionals I en-
countered while a board member. Though flawed, as all we humans
are, they showed wisdom, compassion, determination, and spirit.
After six months, I still miss them.
POSTSCRIPT
When I showed an earlier draft of this work to several col-
leagues and friends,44 a few objected to the lack of recommenda-
tions for change. They thought that I should try to identify
weaknesses in the IRB process and ways to avoid them. One of the
most intelligent of these critics was Marcellina, a physician and for-
mer medical examiner who had gone to the law school where I
teach, and who was now representing doctors and hospitals in a
nearby community, as well as serving on an IRB. Unlike the other
objectors, Marcellina offered some possible recommendations.
First of all, she had doubts-and correctly thought that I did
too-about the ability of "hypereducated" people to write for a sev-
enth grade audience. Her solution to this problem was technologi-
cal: a computer program that scores written material for
readability, while providing suggestions for improvement (she even
sent me several printouts from the program, comparing a few ex-
cerpts from documents in my memoir to her revisions of the
excerpts.)
Initially I was surprised that Marcellina had not seen reference
to the use of a similar computer program, though I quickly realized
44. See supra first asterisk.
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that reading the footnotes closely45 is probably too much to ask of a
reader. Because of this previous use, I was familiar with the com-
puter program Marcellina described, and consider it helpful-up to
a point. Such programs are much better at identifying a readability
problem than they are at showing a solution. In the final analysis, it
takes a lot of human labor to produce writing that patients can un-
derstand. The various documents in this memoir may perhaps pro-
vide some starting points for that difficult work.
Marcellina also bemoaned the fact the IRB members and those
who submit research projects to IRB's rarely receive any training.
Consequently, the board members either do nothing, suffer burn out
from work overload, or alienate enough of the hospital power struc-
ture to be discharged; for their part, the researchers become either
contemptuous or frustrated. Required training for all concerned
was Marcellina's recommendation for solving this problem.
But there was little in the way of training that could have pre-
pared me for my experience as an IRB member. As previously
noted,4 it is difficult to give a meaningful explanation of the work
of an IRB to someone who is not already familiar with that work.
On-the-job training, either as a board member or as a researcher
subject to board review, seems required. About all that can be done
beforehand is to gain a general understanding of the issues with
which IRB members grapple-another service I hope this memoir
provides.
Regarding the potential power struggle between researchers and
the board that reviews their work, Marcellina recommended that
IRB members invoke the power of external agencies, such as the
state boards that regulate medical professionals. The power of these
boards to revoke or condition medical licenses is a saber that a
"savvy" board, as she put it, could rattle at appropriate times to
curb overzealous researchers.
Again, my experience makes be dubious. Certainly those of us
on the IRB who championed patient interests could have been more
savvy, but I do not think the outcome would have been any differ-
ent. The destiny of a hospital IRB is to be a marginal body, and
any board that seeks more influence than this will fail, sooner or
later. The unsurprising lesson of my IRB service is that there is a
limit to what can be accomplished within any power structure, espe-
cially one peopled with professionals. But a board member willing
45. See supra note 25.
46. See supra text preceding note 15 (discussing the work of my student assistant).
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to work within those limits can accomplish quite a lot. That is an-
other point I hope this memoir underscores.
As I thanked Marcellina for her comments, I thought to myself
that I was not likely to use them. But a few months later, when the
editors of Health Matrix recommended adding a postscript indicat-
ing "how things could be better" on an IRB, I thought again of her
suggestions, and I think that they point the way to improving the
IRB process. But like all specifics, they tell only a part of the story.
This week I wrote this postscript, in November 1991, I ran into
Dr. Titus, once again at a concert. I was pleased to see him, and
enthusiastically wished that he convey my greetings to all those I
knew at the hospital. He misunderstood my comment, pointing out
in a good-natured fashion that there were few persons on the cur-
rent IRB whom I knew. Then he added that he had decided to
leave the board at the end of the year-"just too many other things
to do," he said. He was moving on, and as the concert intermission
was about over, I had to be moving on, too.
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